SCODiA Report by MLBI Lab

Single-Cell Resolution of Cellular Dynamics and Pathway Dysregulation in Human Colonic Inflammation

This report presents a comprehensive single-cell RNA-sequencing analysis of human colon tissue, delineating the cellular and molecular landscape of colonic inflammation. UMAP visualizations reveal distinct clustering of 'Inflamed' cells and robust hierarchical cell type annotations. Population analyses indicate a pronounced shift in immune cell composition in inflammation, with increased B cells, plasma cells, macrophages (M1 and M2B subsets), and specific T cell subsets (Treg, Tfh, Th22, CD8 Exhausted). Paradoxically, Th1, Th17, and CD8 Memory T cell proportions are decreased. Cell-cell interaction analyses highlight upregulated inflammatory signaling (IFN-γ, Prostaglandin E2, CXCL12-CXCR4, VCAM1-integrin) in inflamed tissue, involving immune, epithelial, and stromal cells. Surfaceome marker expression on Intestinal Epithelial cells (MHC Class II, CEACAM5, ITGA6/ITGB1), Macrophages (FCGR2A, CD86, ICAM1, IL10RA), Fibroblasts (PDGFRA, MMP14, VCAM1), and CD4+ T cells (CD44, CD27) reveals condition-specific activation profiles. Gene Set Enrichment Analysis (GSEA) shows broad activation of immune and inflammatory pathways, metabolic reprogramming, and enrichment of cancer-related pathways across multiple cell types in 'Inflamed' colon, with 'Non-inflamed' tissue often displaying an intermediate or subtly activated molecular signature distinct from 'Healthy' controls. These findings collectively provide a high-resolution map of colonic inflammation, identifying key cellular players, communication networks, and dysfunctional pathways.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type in Colon Single-Cell RNA-seq Data
2. Major Cell Type Score Visualization on UMAP
3. Marker Gene Expression Across Colonic Cell Subsets
4. Cellular Population Analysis of Minor Cell Types in Human Colon Across Inflammatory Conditions
5. T Cell and ILC Subset Population Dynamics in Colonic Inflammation
6. Colonic T Cell Subset Population Dynamics in Inflammation
7. Macrophage Subset Population Analysis in Colonic Inflammation
8. Macrophage (M2B) Subset Population Differences Across Colonic Conditions
9. Analysis of Cell-Cell Interaction Patterns in Colonic Tissues Across Health and Inflammation
10. Condition-Specific Cell-Cell Interaction Patterns in Colonic Inflammation
11. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colonic Inflammation
12. Macrophage Surfaceome Marker Expression in Colonic Inflammation
13. Fibroblast Condition-Specific Surfaceome Marker Expression in Colonic Tissue
14. T cell CD4+ Condition-Specific Surfaceome Markers in Colonic Tissue
15. Macrophage Gene Ontology Enrichment Analysis in Colonic Inflammation
16. Gene Set Enrichment Analysis Reveals Cell-Type-Specific Pathway Dysregulation in Colonic Inflammation
17. Discussion
18. Query List

0. Dataset overview

Dataset Summary

• Dimensions: 88,167 cells and 18,151 genes.
• Species & Tissue: Human, Colon tissue.
• Conditions: Includes 'Non-inflamed', 'Inflamed', and 'Healthy' conditions, with 'Healthy' serving as the reference condition for comparative analyses.
• Cell Type Annotations: Comprehensive annotations are available at three hierarchical levels:
• celltype_major: Plasma cell, T cell, Myeloid cell, unassigned, B cell, Mast cell, Intestinal Epithelial cell, Endothelial cell, Stromal cell, Enteric neuron.
• celltype_minor: Plasma cell, T cell CD8+, Macrophage, T cell CD4+, unassigned, Dendritic cell, B cell, NK cell, Mast cell, Intestinal Epithelial cell, ILC, Endothelial cell, Fibroblast, Smooth muscle cell, Enteric glial cell.
• celltype_subset: Plasma cell, T cell (Cytotoxic), T cell (CD8 Memory), Macrophage (M2A), T cell (CD4 Memory), Macrophage (M2B), Macrophage (M1), T cell (Th22), unassigned, DC (Classical), T cell (CD8 Exhausted), Macrophage (M2D), T cell (Treg), T cell (CD4 Naive), B cell (Breg), NK cell, Mast cell, T cell (Tfh), B cell (Follicular), T cell (Th2), DC (Inflammatory), T cell (Th1), B cell (Memory), Macrophage (M2C), T cell (Th17), Goblet cell, DC (Plasmacytoid), B cell (MZ), T cell (CD8 Naive), Tuft cell, T cell (Th9), ILC1, ILC3, ILC2, Endothelial tip cell, ILCreg, Paneth cell, Crypt cell, Fibroblast, Smooth muscle cell, Enteroendocrine cell, Enteric glial cell, Enterocyte, Enterochromaffin cell, Microfold cell, Endothelial cell, Lymphatic Endothelial cell.
• Metadata (obs columns): Includes celltype, nGene, nUMI, Subject, Health, Location, Sample, n_genes_by_counts, total_counts, total_counts_mt, pct_counts_mt, celltype_org, sample, condition, sample_ext, celltype_major, celltype_minor, celltype_subset, cluster.
• Gene Metadata (var columns): Includes mt, n_cells_by_counts, mean_counts, pct_dropout_by_counts, total_counts, variable_genes.
• Tumor Identification: Tumor identification was not requested for this dataset.
• CNV Estimates: No CNV estimates are available for this dataset.

Precomputed Results

• Cell-Cell Interaction (CCI): Results from CellPhoneDB are available per condition (uns['CCI']) and per sample (uns['CCI_sample']). Data includes gene_pair, cell_pair, gene_A, gene_B, cell_A, cell_B, pval, mean.
• Differential Gene Expression (DEG): Results are available for each celltype_minor, comparing one condition versus the rest (uns['DEG']) or versus the reference condition (uns['DEG_vs_ref']). Data includes log2_FC, pval, pval_adj, mean_test, mean_ref, nz_pct_test, nz_pct_ref, nz_pct_score, nz_pct_pval, gene, Rp.
• Gene Set Enrichment Analysis (GSEA): Results are available for each celltype_minor, comparing one condition versus the rest (uns['GSEA']) or versus the reference condition (uns['GSEA_vs_ref']). Data includes Name, ES, NES, NOM p-val, FDR q-val, FWER p-val, Tag %, Gene %, Lead_genes, -log(p-val), -log(q-val), Term.
• Gene Ontology (GO/GSA): Results are available for each celltype_minor, comparing one condition versus the rest (uns['GSA_up']) or versus the reference condition (uns['GSA_vs_ref_up']). Data includes pval, pval_adj, genes, overlap, pw_size, -log(p-val), -log(q-val), Term, Ind.

1. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type in Colon Single-Cell RNA-seq Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, which are dimensionality reduction visualizations of single-cell RNA-sequencing data. These plots project high-dimensional gene expression data into a 2D space, where cells with similar gene expression profiles cluster together. The UMAPs are colored by different metadata categories: 'condition', 'sample', 'celltype_major', 'celltype_minor', and 'celltype_subset', to evaluate the overall data structure, identify potential batch effects, and assess the quality and distribution of cell type annotations across different biological contexts.

Visual Summary

Condition UMAP

The UMAP colored by condition shows a notable separation of cells based on their inflammatory state.

• Healthy (dark red) and Non-inflamed (dark purple) cells largely overlap and form several dense, contiguous clusters across the UMAP, suggesting similar underlying cellular compositions and states.
• Inflamed (yellow) cells exhibit a distinct distribution. While they overlap with Healthy and Non-inflamed cells in some regions, they also form unique clusters or expand into areas less populated by the other two conditions, particularly in the central and upper-left portions of the embedding. This suggests condition-specific cellular populations or states are associated with inflammation.

Sample UMAP

The UMAP colored by sample shows a high degree of intermixing of cells from different samples (represented by various colors) across the entire embedding. This indicates that the primary drivers of the UMAP structure are biological differences between cell types and states, rather than technical variations or batch effects originating from individual samples. While some subtle enrichments of specific samples in certain regions might exist, the overall pattern suggests a well-integrated dataset.

Cell Type UMAPs (Major, Minor, Subset)

The UMAPs colored by celltype_major, celltype_minor, and celltype_subset progressively illustrate the hierarchical organization of cell populations:

• celltype_major: This plot clearly resolves broad categories like Intestinal Epithelial cell (Ent.Epi, orange), T cell (blue), Myeloid cell (light green), and B cell (dark red) into distinct, well-separated clusters. Stromal cell and Endothelial cell also form identifiable groups. unassigned cells (dark purple) are sparsely distributed.
• celltype_minor: This level provides finer resolution within the major clusters. For instance, T cell populations are further differentiated into T cell CD4+ and T cell CD8+. Myeloid cell expands into Macrophage, Dendritic cell, and Mast cell. This plot generally shows good separation of these more granular cell types, maintaining distinct clusters.
• celltype_subset: This highest resolution plot further subdivides minor cell types, revealing specific subtypes such as various Macrophage (M1, M2A, M2B, M2C, M2D) populations, different T cell states (e.g., Cytotoxic, CD8 Memory, CD4 Memory, Treg, Th17), and specialized Intestinal Epithelial cell types (e.g., Goblet cell, Paneth cell, Enterocyte). The distinct clustering observed at this level confirms the robustness of the fine-grained annotations and the biological heterogeneity within the colon tissue.

Biological Interpretation

The UMAP visualizations collectively provide strong evidence for the biological heterogeneity of the human colon and reveal important patterns related to colonic inflammation.

1. Inflammation-Associated Cellular Shifts: The distinct clustering of Inflamed cells, which occupy regions separate from Healthy and Non-inflamed cells, strongly suggests that the inflammatory process induces significant shifts in cellular states or composition. This could involve the activation of resident immune cells, infiltration of new immune populations, or changes in the state of stromal and epithelial cells. This pattern aligns with the inferred context of colonic inflammation.
2. Robust Cell Type Annotation: The clear segregation of major, minor, and subset cell types into distinct clusters on the UMAP demonstrates a high quality of cell type annotation. This indicates that the clustering and annotation methods successfully captured biologically meaningful differences in gene expression profiles that define specific cell identities and states within the colon. The hierarchical nature of the annotations is well-supported by the progressive refinement of clusters.
3. Minimal Batch Effects: The intermixing of cells from different samples across the UMAP embedding suggests that technical variation between samples is not obscuring biological signals. This increases confidence that observed differences, particularly those related to condition, are biologically driven rather than artifacts of sample processing.
4. Heterogeneity of Colon Microenvironment: The presence of numerous distinct cell type clusters, especially at the celltype_subset level, highlights the complex cellular ecosystem of the human colon. This includes various immune cells (T cells, B cells, macrophages, DCs, ILCs), epithelial cells (enterocytes, goblet, paneth, tuft, enteroendocrine, crypt cells), and structural cells (fibroblasts, smooth muscle, endothelial, enteric glial cells), all contributing to the tissue's function and response to disease.
5. Unassigned Cells: The presence of 'unassigned' cells indicates populations that either did not meet the criteria for existing annotations or represent rare or novel cell states not yet classified. These cells warrant further investigation to determine their identity and potential biological significance.

Annotation Notes

• The hierarchical cell type annotations (major, minor, subset) are well-supported by the UMAP embeddings, showing clear separation of cell populations at each level of granularity.
• The distribution of 'unassigned' cells appears scattered rather than forming distinct clusters, suggesting they may represent cells with ambiguous gene expression profiles, doublets, or low-quality cells, or potentially very rare cell types not yet fully characterized. Further manual curation or re-clustering could be beneficial for these cells.
• The consistent clustering of Healthy and Non-inflamed conditions indicates that at the transcriptional level, these two states share significant similarity, which might imply 'Non-inflamed' could represent areas adjacent to inflammation but not directly involved, or quiescent disease. This would require further investigation using DEG or GSEA analyses.

2. Major Cell Type Score Visualization on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the "HiCAT_major_score" for various major cell types across the UMAP (Uniform Manifold Approximation and Projection) embedding. This scoring approach provides a continuous measure of how strongly each cell expresses the gene signature associated with a particular major cell type. This is compared against the discrete celltype_major annotations to assess the consistency and confidence of cell type assignments within the single-cell RNA-seq dataset from human colon tissue, especially relevant in the context of colonic inflammation.

Visual Summary

The visualization consists of multiple UMAP plots. The first nine plots display the "HiCAT_major_score" for individual major cell types: T cell, Plasma cell, B cell, Myeloid cell, Mast cell, Endothelial cell, Stromal cell, Enteric neuron, and Intestinal Epithelial cell. In these plots, higher scores are indicated by warmer colors (yellow/green), while lower scores are represented by cooler colors (purple). The final plot shows the discrete celltype_major assignments, with each major cell type represented by a distinct color.

Key observations are:

• Concordant Scoring: For each major cell type, regions displaying high "HiCAT_major_score" for that specific cell type strikingly align with the corresponding clusters labeled with the same cell type in the celltype_major annotation plot. For example, the cluster identified as "T cell" in the discrete annotation shows the highest "HiCAT_major_score: T cell" intensity.
• Distinct Cell Populations: The UMAP embedding clearly separates different major cell populations into distinct clusters. The score plots further emphasize this separation by showing high specificity; cells within a particular cluster score highly for their assigned cell type and very low for other cell types.
• Score Distribution: The scores generally show a gradient, with peak intensity at the core of each cluster and gradually decreasing towards the cluster boundaries, suggesting continuous confidence in cell identity across the embedding.

Biological Interpretation

The high concordance between the continuous "HiCAT_major_score" and the discrete celltype_major annotations signifies robust and reliable cell type identification within this single-cell dataset.

• Annotation Quality: The clear and specific localization of high scores for each cell type to its corresponding cluster validates the quality of the cell type annotation. This suggests that the gene signatures used to define each major cell type are highly discriminatory and accurately capture the distinct biological identities of the cells.
• Heterogeneity within Clusters: While each major cell type forms a distinct cluster, the varying intensity of the HiCAT score within a cluster might indicate subtle heterogeneity or transitional states that are not captured by the major cell type annotation level. However, for major cell types, the scores are generally high throughout their respective regions.
• Relevance to Colonic Inflammation: In the context of colonic inflammation, accurate cell type identification is fundamental. Immune cells (e.g., T cells, B cells, Plasma cells, Myeloid cells, Mast cells) are central to the inflammatory response, while structural cells (Intestinal Epithelial cells, Endothelial cells, Stromal cells) and neuronal cells (Enteric neurons) play crucial roles in tissue integrity, immune cell trafficking, and local regulation, all of which are impacted by inflammation. The distinct identification of these cell types provides a solid basis for further downstream analyses, such as differential gene expression or cell-cell interaction studies, to uncover condition-specific biological mechanisms.

Annotation Notes

The strong agreement between the major cell type scores and the assigned celltype_major labels on the UMAP provides confidence in the overall quality and specificity of the cell type annotations. This robust annotation is crucial for the interpretability of subsequent analyses, ensuring that downstream findings related to gene expression, pathway enrichment, or cell-cell communication are attributed to correctly identified cell populations. The clear visualization supports that the major cell types are well-resolved and distinctly represented in the UMAP space.

3. Marker Gene Expression Across Colonic Cell Subsets

[Analysis Visualization Results]...

Analysis Overview

This dot plot visualizes the expression of key marker genes across different celltype_subset populations identified in the single-cell RNA-seq data from human colon tissue. The analysis aims to assess and confirm the identity of these granular cell subsets based on their unique transcriptional profiles. Each dot in the plot represents a specific gene's expression within a cell type subset: the color intensity indicates the mean expression level of the gene in that group (redder means higher expression), and the size of the dot reflects the fraction of cells within the group that express the gene (larger means higher fraction). Marker genes were automatically identified, and target_cell was set to None to display markers for all identified cell type subsets. The gene labels are rotated by 45 degrees for improved readability.

Visual Summary

The dot plot effectively showcases distinct expression patterns for a wide array of cell type subsets, generally demonstrating good specificity of marker genes for their assigned cell populations.

• Distinct Cell Type Clusters: Clear diagonal blocks of high expression (darker, larger dots) are observed for most celltype_subset groups, indicating that the identified marker genes are highly specific and expressed by a large fraction of cells within their respective annotated populations. This pattern is particularly evident for:
• B cell subsets: Genes like POU2F2 (OCT2) and MS4A1 (CD20) are highly specific to B cell (Breg), B cell (Follicular), B cell (MZ), and B cell (Memory) populations.
• Endothelial cells: CDH5, ESAM, and CLDN5 show strong and specific expression in Endothelial cell and Endothelial tip cell populations.
• Enteric glial cells: S100B and LGI4 are highly specific.
• Intestinal Epithelial cell subsets: Each epithelial subset displays unique markers: LGR5 for Crypt cell, CHGA for Enterochromaffin and Enteroendocrine cells, FABP1/FABP2 for Enterocyte, MUC2/TFF3 for Goblet cell, SPINK4 for Microfold cell, ITLN1/KLK1/ZG16 for Paneth cell, and TRPM5 for Tuft cell. These patterns largely conform to known epithelial cell identities in the colon.

Immune cell subsets:

• Mast cells: TPSAB1 (Tryptase) is a highly specific marker.
• Dendritic cells: Genes like IRF8 show enriched expression in DC (Classical) and DC (Plasmacytoid) subsets.
• Macrophages: IFITM3, FCN1, S100A8, S100A9 show differential expression across various macrophage subsets (M1, M2A, M2B).
• Plasma cells: XBP1 and TNFRSF17 (BCMA) exhibit strong and specific expression.
• NK cells: KLRB1 (CD161), NKG7, GZMA, GZMB, PRF1 are highly expressed.
• T cell subsets: Pan-T cell markers (CD3D, CD3E, CD3G) are broadly expressed across T cell populations, with CD4 and CD8A/CD8B showing expected specificity for CD4+ and CD8+ T cell subsets, respectively. Cytotoxic T cells are marked by GZMA, GZMB, PRF1. T regulatory cells (Treg) are characterized by markers like CTLA4, LAG3, and TIGIT.
• Stromal cells: Fibroblast cells show specific expression of DCN, COL1A1/A2, and LUM, while Smooth muscle cells express ACTA2 (Alpha-SMA), MYL9, and CALD1.
• Common Markers: A distinct section labeled "common markers" (red box on the far right) shows genes that are broadly expressed across many or most cell types. These markers, while not useful for cell type discrimination, may represent housekeeping genes or genes involved in general cellular functions.
• Cell Group Size: The bar chart on the right indicates the number of cells contributing to each celltype_subset, providing context for the robustness of marker identification for each group. For instance, Macrophage (M2A) has a substantial number of cells (22005), while some subsets like ILC1 (78 cells) or T cell (Th9) (61 cells) are smaller.

Biological Interpretation

The observed marker gene expression patterns align well with established biological knowledge of cell identities within the human colon, supporting the robust annotation of the celltype_subset populations.

• Immune Cell Lineage Confirmation: The distinct expression of lineage-specific markers like MS4A1 (CD20) for B cells UniProt: P11836, CD3 complex genes for T cells, and TPSAB1 for Mast cells confirms the presence and identity of these key immune players in the colon. The differentiation of T cells into CD4+, CD8+, and various helper/regulatory subsets (e.g., Treg with CTLA4 and LAG3 PubMed search: CTLA4 LAG3 Treg) is also well-supported. The presence of Macrophage M1/M2 subtypes, defined by distinct marker sets, suggests diverse immune functions and polarization states, which are particularly relevant in the context of colonic inflammation.
• Epithelial Cell Diversity: The specific markers for various intestinal epithelial cell types (Crypt, Goblet, Paneth, Enteroendocrine, Enterocyte, Microfold, Tuft cells) indicate the successful capture of the functional specialization of the gut lining. For example, LGR5 marks intestinal stem cells in the crypts GeneCards: LGR5, while MUC2 is characteristic of mucin-producing Goblet cells GeneCards: MUC2. CHGA and SCGN mark enteroendocrine cells responsible for hormone production.
• Stromal and Endothelial Components: The expression of genes like DCN, COL1A1/A2 (collagens), and LUM in Fibroblasts and ACTA2 (smooth muscle actin) in Smooth muscle cells confirms the presence of distinct stromal compartments critical for tissue structure and function. Endothelial markers like CDH5 (VE-cadherin) GeneCards: CDH5 confirm the vascular network.
• Context of Colonic Inflammation: Given the inferred biological context of colonic inflammation, the robust identification of these cell subsets is crucial. For instance, the presence of distinct T cell and macrophage subsets (including different M2 macrophage polarization states) is highly relevant, as these cells play pivotal roles in orchestrating and resolving inflammatory responses in the gut. The clarity of these annotations provides a solid foundation for further investigations into how these specific cell populations might be altered in inflamed versus non-inflamed or healthy conditions.

Annotation Notes

The plot_markers_and_expression_dot analysis provides strong evidence supporting the quality and accuracy of the celltype_subset annotations within this AnnData object.

• Robust Cell Type Identification: The high specificity and enrichment of classic marker genes within their respective celltype_subset populations indicate that the cell clustering and subsequent annotation process were effective in delineating biologically meaningful populations. The clear diagonal patterns across the plot confirm that most cell type subsets are well-defined by unique transcriptional signatures.
• Granularity of Subsets: The ability to distinguish fine-grained subsets such as various B cell, T cell, Macrophage, and Intestinal Epithelial cell types underscores the high resolution of the single-cell data and the annotation approach. This granularity is essential for understanding complex biological processes like colonic inflammation where subtle shifts in cell states and proportions can have significant impact.
• Minor Overlaps/Ambiguities: While most markers are highly specific, some genes might show lower-level expression or expression in a small fraction of cells in unexpected groups. Such minor overlaps could indicate shared lineage features, transient states, or biological heterogeneity not fully captured by the celltype_subset labels. However, these instances do not detract significantly from the overall robustness of the annotations.
• Confidence in Downstream Analyses: The clear validation of cell type identities through this marker expression plot provides high confidence for subsequent differential expression, gene set enrichment, or cell-cell interaction analyses that rely on accurate cell type assignments.

4. Cellular Population Analysis of Minor Cell Types in Human Colon Across Inflammatory Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the proportional distribution of minor cell types within individual samples across three distinct conditions: Healthy, Inflamed, and Non-inflamed human colon tissue. Each bar represents a single sample, and the segments within each bar show the relative abundance of different cell types. This allows for a direct comparison of cellular composition shifts associated with colonic inflammation.

Visual Summary

The visualization reveals clear differences in the cellular composition across the three conditions, particularly between the Healthy and Inflamed states.

• Healthy Condition: Samples in the 'Healthy' group are generally characterized by a higher proportion of structural and epithelial cells, predominantly Intestinal Epithelial cells (light yellow). Immune cell populations like B cells (dark red), Plasma cells (light green), and T cells (light teal and blue) are present but at lower relative abundances compared to inflamed tissues.
• Inflamed Condition: The 'Inflamed' samples show a distinct shift towards a higher proportion of immune cells. There is a prominent increase in B cells (dark red) and Plasma cells (light green), often constituting a significant portion of the total cells. T cells (CD4+ and CD8+), Macrophages (pale yellow), and Dendritic cells (red) also appear to be more abundant. Concomitantly, the relative proportion of Intestinal Epithelial cells (light yellow) is noticeably reduced in many inflamed samples, often replaced by infiltrating immune cells. Significant heterogeneity in immune cell infiltration is observed among individual 'Inflamed' samples.
• Non-inflamed Condition: The 'Non-inflamed' samples exhibit a cellular profile that is generally intermediate between 'Healthy' and 'Inflamed'. While many 'Non-inflamed' samples resemble 'Healthy' tissue with a higher epithelial cell content, some samples within this group show a moderate increase in B cells and other immune cells, similar to, but typically less pronounced than, the 'Inflamed' samples. This suggests variability or a spectrum of states within the 'Non-inflamed' category.

Biological Interpretation

The observed shifts in minor cell type populations provide strong evidence for an active inflammatory process in the colon.

• Immune Cell Infiltration and Activation: The most striking feature of the 'Inflamed' condition is the robust infiltration and expansion of various immune cell types.
• B cells and Plasma cells: The substantial increase in B cells and their differentiated counterparts, Plasma cells, suggests an active humoral immune response, potentially involving local antibody production within the inflamed colon. This is a common feature in chronic inflammatory conditions, including inflammatory bowel diseases (IBD) [1].
• T cells (CD4+ and CD8+): The elevated proportions of both CD4+ helper T cells and CD8+ cytotoxic T cells indicate a significant cell-mediated immune response, crucial for coordinating and executing inflammation [2].
• Myeloid Cells (Macrophages, Dendritic cells): The visible contributions of Macrophages and Dendritic cells in inflamed tissues highlight their role as professional antigen-presenting cells, which initiate and propagate immune responses by processing antigens and secreting pro-inflammatory cytokines [3].
• Epithelial Barrier Compromise: The proportional reduction of Intestinal Epithelial cells in 'Inflamed' samples is consistent with the epithelial damage, architectural distortion, and displacement by immune infiltrates commonly seen in colonic inflammation. A compromised epithelial barrier is a hallmark of many gastrointestinal inflammatory diseases.
• Heterogeneity of Inflammatory Response: The considerable sample-to-sample variability within the 'Inflamed' group underscores the complex nature of colonic inflammation. This heterogeneity could reflect different disease subtypes, varying stages of disease activity, or individual patient responses.
• "Non-inflamed" as a Spectrum: The 'Non-inflamed' condition, showing a mix of healthy-like and mildly inflamed-like cellular compositions, suggests that this group may encompass a spectrum from truly quiescent states to areas with subclinical inflammation or those in remission.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for understanding and managing colonic inflammation.

• Biomarker Discovery and Disease Stratification: The distinct increases in specific immune cell populations (e.g., B cells, Plasma cells, T cells) in inflamed tissue could serve as valuable cellular biomarkers for diagnosing, staging, and monitoring disease activity in conditions like IBD. Variations in these cellular profiles could help stratify patients for more personalized treatment strategies.
• Therapeutic Targeting: The identification of expanding cell populations like B cells and T cells points to potential therapeutic targets. Modulating the activity or abundance of these specific immune cell subsets could offer novel or improved treatment avenues for chronic colonic inflammation.
• Monitoring Treatment Response: Changes in the proportions of these key cell types could be utilized to monitor the efficacy of anti-inflammatory therapies, providing objective measures of treatment response at the cellular level.
• Understanding Pathogenesis: This cellular-level insight into colonic inflammation enhances our understanding of the underlying immunological mechanisms, which is critical for developing more effective interventions.

---

References:

1. B cells and Plasma cells in inflammation: Learn more about the role of B cells and plasma cells in inflammatory diseases, including IBD, on resources like PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=B+cells+plasma+cells+colonic+inflammation
2. T cells in inflammation: For information on the diverse roles of T cells in inflammation, refer to reviews on PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=T+cells+colonic+inflammation
3. Macrophages and Dendritic cells in inflammation: For details on the function of macrophages and dendritic cells in inflammatory responses, search resources like PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=macrophages+dendritic+cells+colonic+inflammation

5. T Cell and ILC Subset Population Dynamics in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis presents population bar plots depicting the relative proportions of various T cell subsets and Innate Lymphoid Cell (ILC) populations across individual samples, stratified by their health condition: Healthy, Inflamed, and Non-inflamed. The data is derived from human colon tissue, and the plots provide insights into the immunological landscape of the adaptive and innate lymphoid compartments in different disease states, particularly focusing on the context of colonic inflammation. Each bar represents a single sample, and the stacked segments within each bar show the percentage contribution of each cell type.

Visual Summary

The stacked bar plots illustrate the relative abundance of 19 distinct T cell and ILC subsets within the total T cell/ILC compartment across individual samples from Healthy, Inflamed, and Non-inflamed conditions.

General Composition in Healthy and Non-inflamed Samples:

• In both Healthy and Non-inflamed conditions, the T cell compartment is predominantly composed of T cell (CD4 Memory), T cell (CD8 Memory), and T cell (Cytotoxic) subsets. T cell (CD4 Naive) and T cell (CD8 Naive) are also present in varying but generally smaller proportions.
• T cell (Treg) cells are consistently observed across most samples in both Healthy and Non-inflamed states, albeit in smaller relative frequencies compared to effector/memory T cells.
• Th subsets (Th1, Th2, Th9, Th17, Th22, Tfh), NK cells, and ILCs (ILC1, ILC2, ILC3, ILCreg) constitute minor proportions, though some Th1 and Th17 cells are discernible.
• The overall distribution of these subsets appears remarkably similar between the Healthy and Non-inflamed conditions, suggesting that the "Non-inflamed" samples share a similar T cell and ILC immunological profile with "Healthy" controls.

Shifts in Inflamed Samples:

• In the Inflamed condition, there is a notable increase in the relative proportions of T cell (Cytotoxic) and T cell (CD8 Exhausted) populations in many samples. The light yellow (Cytotoxic) and very light yellow (CD8 Exhausted) segments appear expanded compared to Healthy and Non-inflamed samples. This suggests a heightened cytotoxic response and a potential state of T cell exhaustion, often associated with chronic inflammation or persistent antigen stimulation.
• The proportions of T cell (CD4 Memory) and T cell (CD8 Memory) remain substantial, indicating a robust memory T cell presence.
• Some Inflamed samples also show a modest, yet discernible, increase in certain Th subsets, particularly Th1 and Th17 cells, which are known to be pro-inflammatory.
• While still minor, ILC3 (a red segment) appears slightly more pronounced in a few Inflamed samples compared to the other conditions, suggesting a potential role in the inflammatory process.
• The relative proportion of T cell (Treg) (dark blue) generally appears maintained or slightly reduced relative to the expansion of effector T cells, although a precise quantitative change in proportion requires further statistical analysis.

Biological Interpretation

The observed shifts in T cell and ILC populations provide critical insights into the immune mechanisms active in colonic inflammation.

1. Hallmarks of Active and Chronic Inflammation: The prominent increase in T cell (Cytotoxic) and T cell (CD8 Exhausted) populations in Inflamed colon samples is a strong indicator of an ongoing, robust cytotoxic immune response. Cytotoxic T cells (CTLs) play a crucial role in eliminating infected or dysfunctional cells, and their expansion is typical in inflammation. The emergence of CD8 Exhausted T cells suggests prolonged antigen exposure and T cell activation, which can occur in chronic inflammatory conditions, where T cells might become less effective despite continued stimulation [1].
2. Role of CD4+ T Helper Cells: While CD4 Memory T cells remain abundant, subtle increases in Th1 and Th17 subsets in inflamed tissues are consistent with their established roles in driving intestinal inflammation. Th1 cells are critical for cell-mediated immunity and produce pro-inflammatory cytokines like IFN-γ, while Th17 cells are known for their role in barrier immunity and recruiting neutrophils, both implicated in the pathogenesis of inflammatory bowel diseases (IBD) [2]. The presence of other Th subsets (Th2, Th22, Th9, Tfh) at lower levels suggests a complex interplay of different T helper functions.
3. Regulatory T Cells (Tregs) and Immune Homeostasis: The consistent presence of T cell (Treg) in all conditions underscores their fundamental role in maintaining immune tolerance and preventing excessive inflammation. In inflammatory contexts, the balance between effector T cells and Tregs is crucial; a relative decrease or functional impairment of Tregs can exacerbate inflammation. While this plot shows relative proportions, the maintained presence of Tregs suggests an ongoing attempt by the immune system to counteract the inflammatory response.
4. Innate Lymphoid Cells (ILCs) in Gut Immunity: The slight increase in ILC3 in some inflamed samples is biologically relevant. ILC3s are abundant in the gut and are essential for maintaining intestinal barrier integrity and immune homeostasis, often by interacting with commensal bacteria and producing IL-17 and IL-22 [3]. Their involvement in inflammation can be dual-faceted, contributing to either pro-inflammatory or protective responses depending on the context.
5. "Non-inflamed" Condition: The T cell and ILC composition in "Non-inflamed" samples closely mirrors that of "Healthy" samples. This suggests that "Non-inflamed" may represent areas of the colon that are not overtly inflamed at the time of sampling, or from individuals who do not exhibit active inflammation, providing a valuable control group that helps distinguish active inflammation from baseline immune states.

Clinical or Translational Implications

• Biomarker Identification: The expansion of T cell (Cytotoxic) and particularly T cell (CD8 Exhausted) subsets could serve as valuable cellular biomarkers for diagnosing active colonic inflammation, monitoring disease severity, or assessing chronicity in conditions like Inflammatory Bowel Disease (IBD).
• Therapeutic Targeting: Understanding the precise shifts in Th1, Th17, and Treg populations provides a rationale for developing targeted immunomodulatory therapies. For example, strategies aimed at dampening pro-inflammatory Th1/Th17 responses or augmenting Treg function could be beneficial in managing chronic colonic inflammation. Modulating ILC3 activity could also be a potential avenue.
• Disease Progression and Response to Therapy: Monitoring the proportions of these T cell and ILC subsets over time could help predict disease progression, evaluate the effectiveness of current treatments, and potentially identify patients who might benefit from specific immunotherapies. The distinct profile of Inflamed samples compared to Healthy and Non-inflamed samples highlights the potential for immune cell profiling to inform clinical decision-making.

---

References:

1. T Cell Exhaustion: Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. *Nature Reviews Immunology*, 15(8), 486-499. PubMed search link
2. Th1 and Th17 in IBD: Neurath, M. F. (2014). IL-12 and IL-23 in inflammatory bowel diseases. *Current Opinion in Gastroenterology*, 30(4), 384-389. PubMed search link
3. ILC3 in Gut: Klose, C. S. N., & Artis, D. (2016). Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. *Nature Immunology*, 17(7), 765-774. PubMed search link

6. Colonic T Cell Subset Population Dynamics in Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots visualizing the proportional abundance of various T cell and innate lymphoid cell (ILC) subsets across different conditions: "Non-inflamed," "Inflamed," and "Healthy" within human colon tissue. The proportions are calculated based on single-cell RNA sequencing data. Statistical significance (p-values) for pairwise comparisons between conditions are indicated on the plots, with a cutoff of p < 0.1 used for identifying statistically significant differences. The goal is to identify T cell populations that show significant shifts in their proportions in response to colonic inflammation.

Visual Summary

The box plots reveal several statistically significant (p < 0.1) and near-significant changes in T cell subset proportions across the conditions:

• Treg cells: Show significantly higher proportions in both "Non-inflamed" (p=0.00388) and "Inflamed" (p=0.00348) conditions compared to "Healthy." The difference between "Non-inflamed" and "Inflamed" is not statistically significant (p=0.0992, borderline).
• T cell (CD8 Exhausted): Displays a significantly increased proportion in the "Inflamed" condition compared to "Healthy" (p=0.00468). A trend towards higher proportions is also observed in "Non-inflamed" versus "Healthy" (p=0.0944).
• Tfh cells: Exhibited significantly higher proportions in the "Inflamed" condition compared to "Healthy" (p=0.0104). The "Non-inflamed" condition also shows a trend of higher Tfh cells compared to "Healthy" (p=0.0818).
• Th22 cells: Are significantly increased in proportion in the "Inflamed" condition compared to "Healthy" (p=0.0171). The comparison between "Non-inflamed" and "Inflamed" is borderline significant (p=0.0586), with "Inflamed" showing a higher trend.
• T cell (CD8 Memory): Demonstrates a significantly *lower* proportion in the "Inflamed" condition compared to "Healthy" (p=0.0226).
• Th17 cells: Also show a significantly *lower* proportion in the "Inflamed" condition compared to "Healthy" (p=0.0314). A trend of lower proportion is observed in "Inflamed" compared to "Non-inflamed" (p=0.0605).
• Th1 cells: Exhibit a significantly *lower* proportion in the "Inflamed" condition compared to "Healthy" (p=0.0359).
• ILC2 cells: Display trends towards higher proportions in both "Non-inflamed" (p=0.0672) and "Inflamed" (p=0.0897) conditions compared to "Healthy," though these are borderline significant.

Biological Interpretation

The observed shifts in T cell subset proportions provide crucial insights into the immune landscape of colonic inflammation.

• Increased Regulatory and Exhausted Populations (Treg, CD8 Exhausted): The significant increase in regulatory T cells (Tregs) in both "Non-inflamed" and "Inflamed" conditions compared to "Healthy" suggests an active immune regulatory response attempting to control or limit inflammation. Tregs are critical for maintaining immune tolerance in the gut. The elevation of CD8 Exhausted T cells in inflammation points towards chronic immune stimulation, leading to T cell dysfunction, which could be a mechanism to prevent excessive tissue damage but also hinders effective pathogen clearance or tumor surveillance in other contexts [PMID: 34183883].
• Elevated Helper and Barrier-Supporting Subsets (Tfh, Th22): The increased proportions of T follicular helper (Tfh) cells in the "Inflamed" state could promote B cell-mediated immunity and local antibody production, which can either contribute to immune pathology or be protective depending on the antigen specificity and antibody class [PMID: 32692233]. The rise in Th22 cells, known for producing IL-22, may indicate an attempt to reinforce epithelial barrier integrity and support tissue repair in the inflamed colon, as IL-22 plays a role in gut epithelial homeostasis and antimicrobial defense [PMID: 31051515].
• Decreased Pro-inflammatory and Memory T cell Proportions (Th17, Th1, CD8 Memory): The most striking findings are the significant *decreases* in the proportions of Th17, Th1, and CD8 Memory T cells in the "Inflamed" condition compared to "Healthy."
• Th17 and Th1 cells: These are well-known pro-inflammatory subsets involved in various inflammatory diseases, including inflammatory bowel disease (IBD). Their proportional *decrease* in the inflamed colon is counter-intuitive if considering an active acute inflammation characterized by robust Th1/Th17 responses. This might suggest:

1. Relative dilution: Other immune cell populations (e.g., myeloid cells, other T cell subsets like Tregs or exhausted cells) might be expanding more dramatically, thereby diluting the proportion of Th1/Th17 cells even if their absolute numbers are elevated.
2. Specific inflammatory stage/type: The "Inflamed" condition in this dataset might represent a chronic or resolving inflammatory state rather than an acute, highly active one, where Th1/Th17 cells may be less dominant or undergo apoptosis/migration.
3. Dysregulation or exhaustion: These cells might be functionally impaired or undergoing exhaustion, similar to CD8 T cells, leading to changes in their persistence or phenotype, or they may migrate out of the tissue.

• CD8 Memory T cells: The reduction in CD8 Memory T cells in the "Inflamed" condition could indicate a shift towards other CD8 phenotypes (e.g., exhausted cells as observed) or selective cell death. This may impair long-term protective immunity.
• Borderline Increase in ILC2: The trend of increased ILC2 proportions in "Non-inflamed" and "Inflamed" conditions compared to "Healthy" suggests a potential role for type 2 innate immunity in the colon, possibly related to tissue repair, anti-helminth immunity, or contributing to specific forms of inflammation [PMID: 33446973].

Overall, the picture emerging from these T cell subset shifts in colonic inflammation is complex, indicating a dynamic interplay between pro-inflammatory responses, regulatory mechanisms, and T cell exhaustion. The proportional decrease in Th1 and Th17 cells, alongside an increase in Tregs and exhausted CD8 T cells, highlights the need for a comprehensive understanding of absolute cell numbers and functional states rather than just proportions.

Clinical or Translational Implications

These findings have several potential clinical implications for understanding and managing colonic inflammation:

• Biomarkers of Disease State: The identified T cell subsets with altered proportions (e.g., increased Tregs, CD8 Exhausted T cells, Tfh, Th22, and decreased Th17, Th1, CD8 Memory) could serve as potential biomarkers for assessing the severity, chronicity, or specific immune profile of colonic inflammatory conditions. Monitoring these populations in biopsies or circulating blood (if applicable) might aid in disease staging or response to therapy.

Therapeutic Targets:

• The increased Tregs suggest that augmenting their function could be a therapeutic strategy to dampen inflammation.
• Conversely, the presence of exhausted CD8 T cells could contribute to impaired immune surveillance or pathogen clearance; strategies to reverse T cell exhaustion might be relevant, although the role of CD8 exhaustion in colonic inflammation needs further investigation.
• The observed proportional decreases in Th17 and Th1 cells in the inflamed state challenge conventional views of IBD pathogenesis and may imply that specific therapies targeting these pathways might be more effective at certain disease stages or in specific patient subgroups, or that the immune response in this cohort is distinct.
• Stratification of Inflammation: The diverse changes in T cell subsets suggest that "colonic inflammation" is not a monolithic entity but may involve different immune signatures. Stratifying patients based on these cellular profiles could lead to more personalized treatment approaches.

7. Macrophage Subset Population Analysis in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional distribution of macrophage subsets (Macrophage M1, M2A, M2B, M2C, M2D) across individual samples from Healthy, Inflamed, and Non-inflamed colonic tissues. The aim is to identify shifts in macrophage polarization states associated with the inflammatory condition in the colon. Macrophages play critical roles in both initiating and resolving inflammation, with different subsets (M1 generally pro-inflammatory, M2 generally anti-inflammatory/pro-resolving) contributing distinct functions.

Visual Summary

The stacked bar plots display the relative proportions of five distinct macrophage subsets (M1, M2A, M2B, M2C, M2D) within the total macrophage population for each individual sample, grouped by condition (Healthy, Inflamed, Non-inflamed).

1. Macrophage (M1) Dominance in Inflammation: In the 'Inflamed' condition, there is a prominent increase in the proportion of Macrophage (M1) cells (dark red bars) across most samples compared to the 'Healthy' condition. M1 macrophages often represent more than 50% and sometimes up to ~70% of the total macrophage population in many 'Inflamed' samples.
2. Reduced Macrophage (M2A) in Inflammation: Concurrently with the increase in M1, there is a noticeable decrease in the proportion of Macrophage (M2A) cells (orange bars) in most 'Inflamed' samples. In 'Healthy' samples, M2A often constitutes a substantial portion, sometimes exceeding M1, but its contribution is significantly diminished in the 'Inflamed' state.
3. Minor Subsets (M2B, M2C, M2D): Macrophage (M2B), (M2C) (yellow hues), and (M2D) (teal) subsets generally represent smaller proportions across all conditions. While their individual contributions fluctuate, no clear and consistent pattern of significant change is immediately apparent for these subsets in 'Inflamed' samples compared to 'Healthy,' although M2D might show a slight reduction in many inflamed samples.
4. Heterogeneity in Non-inflamed Samples: The 'Non-inflamed' group exhibits considerable heterogeneity. Some samples show a macrophage subset distribution similar to 'Healthy' samples (lower M1, higher M2A), while others display a pattern more akin to 'Inflamed' samples (higher M1, lower M2A). This suggests that the "Non-inflamed" category may encompass a spectrum of states, potentially including individuals with subclinical inflammation or those in different stages of disease progression/resolution.
5. Sample-Specific Variability: Within each condition, especially 'Inflamed' and 'Non-inflamed,' there is notable sample-to-sample variability in macrophage subset proportions, indicating a diverse immune landscape among individuals.

Biological Interpretation

The observed shift in macrophage populations is highly indicative of an active inflammatory response in the colon.

• M1 Macrophages in Inflammation: The increase in Macrophage (M1) populations in 'Inflamed' tissues is a classic hallmark of pro-inflammatory responses. M1 macrophages are typically activated by microbial products (e.g., LPS) and pro-inflammatory cytokines (e.g., IFN-$\gamma$, TNF-$\alpha$). They are crucial for host defense, producing reactive oxygen species, nitric oxide, and pro-inflammatory cytokines like IL-1$\beta$, IL-6, IL-12, and TNF-$\alpha$, which exacerbate inflammation and contribute to tissue damage in chronic conditions like inflammatory bowel disease (IBD) [PubMed Search].
• M2A Macrophages and Resolution: The reciprocal decrease in Macrophage (M2A) populations in 'Inflamed' samples suggests a reduction in anti-inflammatory or tissue-repair processes. M2A macrophages are generally induced by IL-4 and IL-13 and are involved in allergic responses, parasitic infections, and wound healing, characterized by expression of arginase 1 (ARG1), resistin-like molecule $\alpha$ (RETNLA), and chitinase-like protein 3 (CHI3L1/Ym1) [PubMed Search]. Their diminished presence may contribute to impaired resolution of inflammation and chronic tissue damage.
• Implications of Non-inflamed Heterogeneity: The mixed profiles in 'Non-inflamed' samples are particularly interesting. This could reflect a spectrum of conditions: truly healthy individuals, individuals with a history of inflammation who are in remission but still harbor an altered immune environment, or individuals with low-grade, subclinical inflammation not yet classified as 'Inflamed'. Further investigations into these 'Non-inflamed' samples, potentially through additional molecular markers or clinical correlations, would be beneficial to understand this heterogeneity.

Overall, the data robustly supports a pro-inflammatory macrophage polarization state (M1 dominance) in colonic inflammation, shifting away from potentially regulatory or tissue-repairing M2A subsets.

Clinical or Translational Implications

The distinct shifts in macrophage subsets observed here have several clinical implications for colonic inflammation:

1. Biomarker Potential: The ratio of M1 to M2A macrophages, or the absolute proportion of M1 macrophages, could serve as a potential biomarker for disease activity or inflammatory status in the colon. Monitoring these changes could provide insights into disease progression or response to therapy.
2. Therapeutic Targeting: The observed M1 dominance in inflamed tissue suggests that therapeutic strategies aimed at modulating macrophage polarization could be beneficial. Approaches that inhibit M1 activation or promote M2 polarization (especially M2A for tissue repair) might help to resolve inflammation and facilitate tissue healing. This could involve targeting specific cytokines (e.g., blocking IFN-$\gamma$ or TNF-$\alpha$ to reduce M1, or administering IL-4/IL-13 to promote M2A) or immune checkpoints.
3. Understanding Disease Pathogenesis: This analysis highlights the importance of macrophage plasticity in colonic inflammation. Understanding the specific factors that drive M1 polarization in the colon and inhibit M2A differentiation could reveal novel mechanistic pathways relevant to the pathogenesis of inflammatory bowel diseases.
4. Stratification of "Non-inflamed" Patients: The heterogeneity within the 'Non-inflamed' group suggests that a subset of these individuals might be at higher risk for developing inflammation or could represent a pre-disease state. Further characterization of their macrophage profiles could help in identifying individuals who might benefit from preventive interventions.

8. Macrophage (M2B) Subset Population Differences Across Colonic Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a box plot visualizing the proportional representation of the Macrophage (M2B) cell subset across three distinct colonic conditions: Non-inflamed, Healthy, and Inflamed. Statistical comparisons between these conditions are provided, indicating where significant differences or trends in cell proportions are observed, based on a p-value cutoff of 0.1 as specified in the analysis parameters. This helps in understanding the dynamic changes in specific macrophage populations in the context of colonic inflammation.

Visual Summary

The box plot reveals notable differences in the proportion of Macrophage (M2B) cells across the conditions:

• The Healthy condition shows the lowest median proportion of Macrophage (M2B) cells.
• Compared to the Healthy condition, the proportion of Macrophage (M2B) cells is significantly higher in the Non-inflamed condition (p = 0.0381).
• The highest proportion of Macrophage (M2B) cells is observed in the Inflamed condition. This increase is statistically significant when compared to the Healthy condition (p = 0.00218).
• Furthermore, the proportion in the Inflamed condition is also significantly higher than in the Non-inflamed condition (p = 0.0791), adhering to the applied p-value cutoff of 0.1 for statistical significance.
• There is considerable variability in cell proportions, particularly within the Inflamed group, as indicated by the spread of individual data points and the box plot range.

Biological Interpretation

Macrophages are critical immune cells involved in both initiation and resolution of inflammation, with diverse functional phenotypes often categorized as M1 (pro-inflammatory) and M2 (anti-inflammatory/regulatory/repair). However, the M2 classification itself is broad, encompassing several subsets (M2a, M2b, M2c, M2d) with distinct activation mechanisms and effector functions.

The observed sequential increase in the proportion of Macrophage (M2B) cells from Healthy to Non-inflamed, and further to Inflamed states, suggests a significant involvement of this specific macrophage subset in the pathogenesis and progression of colonic inflammation. M2B macrophages are distinct; they can be activated by immune complexes in combination with Toll-like receptor (TLR) agonists. Unlike other M2 subsets often associated purely with resolution or tissue repair, M2B macrophages exhibit a more complex phenotype, capable of producing both pro-inflammatory cytokines (e.g., IL-6, TNF-α) and anti-inflammatory cytokines (e.g., IL-10), as well as high levels of antigen-presenting molecules like MHC class II [1, 2].

Their increasing prevalence in inflamed colon tissue indicates that these cells may play a dual role, contributing to the ongoing inflammatory response while potentially also participating in immune regulation or antigen presentation in the inflamed microenvironment. This dynamic shift suggests that M2B macrophages are actively recruited or differentiate *in situ* as inflammation escalates.

Clinical or Translational Implications

The significant enrichment of Macrophage (M2B) cells in inflamed colonic tissue points to their potential as a cellular biomarker for disease activity in colonic inflammatory conditions. Monitoring the proportion of this specific macrophage subset could offer insights into disease severity or response to therapy.

Furthermore, given their mixed pro-inflammatory and regulatory functions, M2B macrophages represent a potential therapeutic target. Understanding the precise mechanisms by which M2B cells are activated and sustained in colonic inflammation, and their net contribution to tissue pathology versus resolution, could pave the way for targeted immunomodulatory strategies. For instance, interventions aimed at skewing M2B macrophage function towards resolution or inhibiting their pro-inflammatory activities might be beneficial in managing inflammatory bowel diseases or other forms of colitis.

---

References

1. M2 Macrophage Polarization:

PubMed Search: "M2B macrophage function"

2. Macrophage Plasticity in Inflammation:

PubMed Search: "macrophage plasticity inflammation gut"

9. Analysis of Cell-Cell Interaction Patterns in Colonic Tissues Across Health and Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB across different conditions: 'Healthy', 'Inflamed', and 'Non-inflamed' human colon tissue, as determined from single-cell RNA sequencing data. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between various cell-cell pairs, providing insights into potential communication dynamics in the colonic microenvironment during different states. The plots display the mean expression level of ligand-receptor pairs (color intensity) and the statistical significance (-log10(p-value), dot size) for interactions deemed significant.

Visual Summary

The three dot plots visualize cell-cell interaction patterns for 'Healthy', 'Inflamed', and 'Non-inflamed' conditions, respectively, highlighting significant ligand-receptor pairs (x-axis) and the interacting cell types (y-axis). A maximum of 80 cell-cell interactions per group are shown.

Key observations across conditions:

Overall Interaction Landscape:

• The 'Inflamed' condition exhibits a visibly richer and more diverse set of highly significant (larger dot size) and highly expressed (yellow/green dots) interactions compared to 'Healthy' and 'Non-inflamed' conditions, particularly involving immune cell populations like T cells and Macrophages, and their interactions with Intestinal Epithelial cells and Fibroblasts.
• The 'Healthy' and 'Non-inflamed' conditions share a baseline of interactions, though 'Non-inflamed' shows some unique or slightly enhanced patterns relative to 'Healthy', suggesting it might represent a state distinct from full health or overt inflammation.

Prominent Interactions in Healthy Colon:

• Interactions such as Prostaglandin E2_byPTGES3-PTGER4 and EFNB1-EPHB2 are prominent within Intestinal Epithelial cell populations, indicating roles in epithelial homeostasis and cell-cell communication.
• CXCL12-CXCR4 signaling is observed between Fibroblasts and immune cells (Macrophages, Plasma cells, T CD4+), suggesting basal mechanisms for immune cell recruitment or stromal support.
• CDH1_integrin_aEb7_complex interactions are noted for Intestinal Epithelial cells, important for epithelial integrity.

Changes in Inflamed Colon:

• Immune Activation & Recruitment: A striking increase in IFNG_Type_II_IFNR signaling is observed in T cell-T cell interactions (T CD8+|T CD8+, T CD4+|T CD4+), a hallmark of active T-cell mediated inflammation. The CXCL12-CXCR4 axis appears to involve a broader range of cell pairs, including Intestinal Epithelial cells, suggesting enhanced immune cell trafficking and communication with non-immune cells in the inflammatory microenvironment.
• Inflammatory Mediators & Adhesion: Prostaglandin E2_byPTGES3-PTGER2/4 interactions show a very high mean expression (yellow dots) in Macrophage-Macrophage and Intestinal Epi-Intestinal Epi interactions, indicating increased prostaglandin-mediated signaling during inflammation. CEACAM5-CEACAM5 and CEACAM6-CEACAM6 interactions become highly prominent involving Intestinal Epithelial cells and Macrophages, reflecting their role in inflammation and adhesion.
• Myeloid Cell Signaling: ANXA1-FPR3 and TYROBP-CD44 interactions are notably strong within Macrophage populations and between Macrophages and Intestinal Epithelial cells, pointing to active myeloid cell responses in inflammation.

Interactions in Non-inflamed Colon:

• The 'Non-inflamed' condition presents a mixed profile. It shares some homeostatic interactions with 'Healthy' (e.g., CDH1_integrin_aEb7_complex in epithelial cells, CXCL12-CXCR4 in fibroblast-immune interactions) and also shows some unique or elevated signals not as strong in 'Healthy', such as IGFBP3_TMEM219 (Fib|Intestinal Epi) and PDGFD-PDGFRB (Fib|Fib), potentially related to tissue remodeling or an altered quiescent state. It lacks the strong T-cell specific IFNG_Type_II_IFNR interactions observed in the Inflamed state.

Biological Interpretation

The observed cell-cell interaction patterns provide significant biological insights into colonic inflammation.

1. Hallmarks of T-cell Driven Inflammation: The robust upregulation of IFNG_Type_II_IFNR (interferon-gamma receptor) interactions among T cells in the 'Inflamed' condition is a strong indicator of an active adaptive immune response. IFN-γ is a key cytokine produced by activated T helper 1 (Th1) cells and cytotoxic T lymphocytes, driving inflammation and immune cell activation. This suggests a prominent role for T-cells in the inflammatory pathology of the colon.
2. Prostaglandin E2 as a Central Inflammatory Mediator: The high expression of Prostaglandin E2_byPTGES3-PTGER2/4 interactions, particularly within macrophages and epithelial cells in the 'Inflamed' state, underscores the critical role of prostaglandins in modulating inflammatory responses. Prostaglandin E2 can exert diverse effects, including vasodilation, pain sensitization, and modulation of immune cell function, making its signaling a central component of colonic inflammation.
3. Adhesion and Immune Evasion in Inflammation: The increased prominence of CEACAM5-CEACAM5 and CEACAM6-CEACAM6 interactions in the 'Inflamed' condition, involving both epithelial cells and macrophages, suggests their involvement in cell adhesion, immune regulation, and potentially pathological processes. CEACAMs are known to be upregulated in various inflammatory conditions and cancers, influencing cell proliferation, differentiation, and immune cell function.
4. Chemokine-Mediated Immune Cell Trafficking: The CXCL12-CXCR4 axis, consistently active in fibroblast-immune cell interactions, appears more broadly engaged in the 'Inflamed' condition. CXCL12 is a potent chemokine that attracts immune cells expressing its receptor CXCR4, such as T cells and macrophages. Its expanded activity in inflammation suggests enhanced recruitment and retention of these cells in the inflamed colon, contributing to the inflammatory infiltrate.
5. Myeloid Cell Activation and Crosstalk: The robust ANXA1-FPR3 and TYROBP-CD44 interactions in macrophages during inflammation highlight the activation of myeloid cells. ANXA1 (Annexin A1) is an anti-inflammatory mediator, and its interaction with FPR3 may be part of a pro-resolving response or a feedback mechanism. TYROBP (DAP12) is an adapter molecule critical for activating various immune receptors on myeloid cells, and its interaction with CD44 in the inflamed state suggests enhanced macrophage activation and potential communication with epithelial cells or other macrophages.
6. Epithelial Homeostasis and Dysregulation: CDH1_integrin_aEb7_complex and EFNB1-EPHB2 interactions, critical for epithelial cell adhesion and barrier function, are consistently observed. Their presence in the inflamed state, even if not dramatically changed in significance, could indicate ongoing attempts at epithelial repair or dysregulation of these fundamental processes in the face of inflammation.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer several potential avenues for clinical and translational applications in managing colonic inflammation.

1. Therapeutic Target Prioritization:

• Targeting IFN-γ Signaling: The strong IFNG_Type_II_IFNR activity in inflamed T cells suggests that therapies aimed at blocking IFN-γ or its receptor could be effective in dampening T-cell mediated inflammation in the colon. This approach has been explored for other autoimmune diseases.
• Modulating Prostaglandin E2 Pathway: Specific inhibition of PTGER2 or PTGER4 receptors, rather than general prostaglandin synthesis (like NSAIDs), might offer more targeted anti-inflammatory effects with fewer side effects by precisely modulating the macrophage and epithelial cell responses observed here.
• Interfering with CEACAM Interactions: Given their upregulation and role in inflammation, blocking CEACAM5 or CEACAM6 interactions could reduce pathological cell adhesion and immune dysregulation in the inflamed colon.
• CXCL12-CXCR4 Axis Inhibition: Targeting CXCR4 could reduce the influx and retention of inflammatory immune cells (T cells, macrophages) in the inflamed colonic tissue, potentially mitigating tissue damage.

2. Biomarker Development: The specific upregulation of interaction pairs like IFNG_Type_II_IFNR in T cells, Prostaglandin E2_byPTGES3-PTGER2/4 in macrophages/epithelial cells, and TYROBP-CD44 in macrophages in the 'Inflamed' condition could serve as diagnostic or prognostic biomarkers for the presence and severity of colonic inflammation. Monitoring these CCI signatures might offer insights into disease activity and treatment response.
3. Experimental Validation: The identified ligand-receptor pairs provide concrete hypotheses for experimental validation. For instance, in vitro co-culture experiments using colon-derived epithelial cells, fibroblasts, and immune cells could investigate the functional consequences of blocking or activating these specific interactions. In vivo models of colitis could further test the therapeutic efficacy of targeting these pathways.
4. Understanding 'Non-inflamed' State: The distinct interaction profile of the 'Non-inflamed' condition warrants further investigation. Understanding the differences between 'Non-inflamed' and 'Healthy' could reveal mechanisms of disease susceptibility, early-stage inflammation, or successful immune regulation, which might be crucial for early intervention strategies.

10. Condition-Specific Cell-Cell Interaction Patterns in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns across 'Healthy', 'Inflamed', and 'Non-inflamed' conditions in human colon tissue, utilizing single-cell RNA-seq data and CellPhoneDB to identify significant ligand-receptor pairs. The objective was to uncover interactions primarily involving major tissue cells, immune cells, and stromal cells that differ significantly between conditions. The dot plot visualizes the scaled log strength of these interactions (color intensity) and their statistical significance (-log10(p-value), dot size) for each sample within each condition. The max_n_items_per_group parameter was set to 60, ensuring that the most statistically significant interactions differentiating the conditions are displayed.

Visual Summary

The dot plot effectively illustrates the differential activity of cell-cell interactions across the three conditions: 'Healthy', 'Inflamed', and 'Non-inflamed' colon samples.

• Overall Pattern: The 'Inflamed' condition exhibits a distinctly higher density of strong and statistically significant interactions (larger, darker red dots) compared to both 'Healthy' and 'Non-inflamed' conditions. This suggests a widespread activation and re-wiring of cellular communication networks during colonic inflammation.
• Healthy Condition: Characterized by a baseline level of interactions. While some interactions are strong, the overall pattern is sparser and less intense than in the 'Inflamed' state. Interactions related to tissue homeostasis, such as certain integrin-mediated epithelial-stromal interactions, appear present.
• Inflamed Condition: Shows a dramatic increase in both the number and strength of interactions. Prominent activation is observed across many cell-cell pairs, particularly those involving immune cells (Macrophages, T cells, Plasma cells), Intestinal Epithelial cells, and Fibroblasts. Several specific signaling pathways, including Prostaglandin D2/E2 signaling, CXCL12-CXCR4, various Integrin-ECM interactions, and immune regulatory axes like SIRPG-CD47, are highly active.
• Non-inflamed Condition: Presents an intermediate or sometimes distinct pattern. While generally showing more activity than 'Healthy' for some pathways, it is typically less pronounced than in 'Inflamed' samples. This condition may represent a state of subclinical inflammation, recovery, or a different type of perturbation.

The clustering of samples within each condition indicates relative homogeneity within groups regarding these CCI patterns, but clear distinctions between the conditions are evident.

Biological Interpretation

The analysis reveals several critical cell-cell interaction pathways that are significantly altered in the context of colonic inflammation. These changes highlight key molecular mechanisms driving the inflammatory process, immune cell recruitment, tissue remodeling, and epithelial barrier dysfunction.

1. Prostaglandin Signaling (e.g., ProstaglandinD2_byPTGES2_PTGER4):

• Description: Multiple interactions involving ProstaglandinD2 or E2 and their receptors (e.g., PTGER4/EP4 receptor, PTGER2/EP2 receptor) are markedly upregulated in Inflamed samples across various cell pairs, including Macrophage-Intestinal Epithelial cell, Plasma cell-T cell CD4+, Fibroblast-Intestinal Epithelial cell, and T cell CD8+-Intestinal Epithelial cell. Prostaglandins are lipid mediators derived from arachidonic acid metabolism, with PGE2 and PGD2 playing crucial roles in inflammation.
• Mechanism in Colonic Inflammation: Elevated prostaglandin signaling, particularly through EP2 and EP4 receptors, promotes vasodilation, increases vascular permeability, and modulates immune cell function (e.g., cytokine production by macrophages, T cell differentiation). In the colon, this contributes to the cardinal signs of inflammation, such as swelling and pain, and influences the inflammatory milieu by shaping immune responses and potentially affecting epithelial barrier integrity. [PubMed Search: "Prostaglandin E2 inflammation colon" or "Prostaglandin D2 inflammation colon"]
• Therapeutic Potential: Inhibitors of prostaglandin synthesis (e.g., NSAIDs, COX-2 inhibitors) or receptor antagonists (e.g., EP4 antagonists) are established anti-inflammatory strategies. Given the widespread activation of this pathway in Inflamed samples, targeted modulation could alleviate inflammatory symptoms.

2. CXCL12-CXCR4 Chemokine Axis (CXCL12_CXCR4):

• Description: Interactions involving CXCL12 and its receptor CXCR4 are notably strong and frequent in Inflamed samples, particularly between Fibroblasts and Macrophages, and Plasma cells and Macrophages.
• Mechanism in Colonic Inflammation: The CXCL12-CXCR4 axis is a critical regulator of immune cell trafficking, homing, and survival. In inflamed tissues, CXCL12 (stromal cell-derived factor-1) secreted by stromal cells (Fibroblasts) and other cells can recruit CXCR4-expressing immune cells (Macrophages, T cells, B cells) to sites of inflammation. This contributes to the accumulation of immune cells in the inflamed colon, sustaining the inflammatory response. [GeneCards: CXCR4]
• Therapeutic Potential: CXCR4 antagonists (e.g., Plerixafor) are clinically used in other contexts (e.g., stem cell mobilization). Targeting this axis could reduce the influx of inflammatory cells into the colon, potentially dampening chronic inflammation.

3. Integrin-Mediated Extracellular Matrix (ECM) Interactions (e.g., COL1A1_integrin a1b1_complex, FN1_integrin a1b1_complex):

• Description: Numerous interactions involving collagens (COLXA), fibronectin (FN1), and various integrin complexes (e.g., integrin a1b1, integrin a2b1) are significantly activated in Inflamed conditions, especially between Fibroblasts and Intestinal Epithelial cells.
• Mechanism in Colonic Inflammation: Integrins are cell surface receptors that mediate cell-ECM adhesion and transmit signals crucial for cell migration, proliferation, differentiation, and tissue remodeling. In colonic inflammation, increased ECM deposition by activated fibroblasts and altered integrin expression on both stromal and epithelial cells contribute to fibrosis, impaired epithelial barrier function, and facilitate immune cell extravasation. This complex interplay drives tissue damage and pathological remodeling observed in chronic inflammatory bowel diseases. [GeneCards: ITGA1 (integrin alpha 1)]
• Therapeutic Potential: Modulating specific integrin pathways could be beneficial. For example, some integrin antagonists are already used in inflammatory conditions to block immune cell trafficking (e.g., Vedolizumab for Crohn's disease/Ulcerative colitis targets α4β7 integrin). Targeting specific ECM-integrin interactions might reduce fibrosis or improve epithelial repair.

4. VCAM1-Integrin α4β1 Adhesion (VCAM1_integrin a4b1_complex):

• Description: Interactions involving VCAM1 (Vascular Cell Adhesion Molecule 1) and integrin a4b1 (also known as VLA-4) appear stronger in the Inflamed condition, particularly between Intestinal Epithelial cells and T cell CD8+.
• Mechanism in Colonic Inflammation: VCAM1 expression is typically upregulated on activated endothelial cells and, as seen here, potentially on epithelial cells in inflamed tissues. It serves as a ligand for integrin a4b1, expressed on leukocytes (e.g., T cells). This interaction is crucial for the adhesion and transendothelial/transepithelial migration of inflammatory cells into the inflamed colonic lamina propria, a hallmark of chronic inflammation. [UniProt: VCAM1]
• Therapeutic Potential: Blocking VCAM1-integrin a4b1 interactions can prevent immune cell infiltration into inflammatory sites. Natalizumab, an antibody targeting integrin α4, has been used in inflammatory conditions like Crohn's disease.

5. SIRPG-CD47 Immune Checkpoint (SIRPG_CD47):

• Description: Interactions between SIRPG (Signal Regulatory Protein Gamma) and CD47 show increased strength in Inflamed samples, notably between Macrophages and Intestinal Epithelial cells, and T cell CD8+ and Macrophages.
• Mechanism in Colonic Inflammation: CD47 is a widely expressed "don't eat me" signal that interacts with SIRP family proteins (SIRPA, SIRPB, SIRPG) on phagocytes (e.g., macrophages) and other immune cells. This axis typically inhibits phagocytosis and regulates immune cell activation. Alterations in SIRPG-CD47 signaling in inflammation could modulate macrophage activity, antigen presentation, and T cell responses, potentially dampening or shaping the immune response to protect host cells from immune attack or, conversely, allowing pathogens to evade clearance. [GeneCards: CD47]
• Therapeutic Potential: CD47-SIRPα blockade is being explored in oncology to promote tumor cell phagocytosis. In inflammatory settings, understanding the precise role of SIRPG-CD47 in different cell types could open avenues for modulating macrophage function and immune tolerance in the colon.

Clinical or Translational Implications

The observed condition-specific cell-cell interaction patterns provide significant insights into the pathobiology of colonic inflammation and offer potential avenues for therapeutic intervention.

• Diagnostic/Prognostic Biomarkers: Specific interaction patterns, particularly the increased density and strength of interactions in the 'Inflamed' state, could serve as biomarkers to differentiate inflammatory activity from 'Healthy' or 'Non-inflamed' states. Further studies could identify specific CCI signatures correlating with disease severity or response to therapy.
• Therapeutic Targets: The upregulation of key inflammatory pathways like Prostaglandin signaling, CXCL12-CXCR4, Integrin-ECM interactions, and VCAM1-integrin α4β1 in the Inflamed condition points to these as promising therapeutic targets.
• Existing Therapies: Targeting VCAM1-integrin α4β1 (e.g., Natalizumab, Vedolizumab) is an established strategy in IBD, reinforcing the relevance of this finding.
• Repurposing/Novel Therapies: Inhibitors of prostaglandin synthesis or specific EP receptors, or CXCR4 antagonists, could be explored for their efficacy in colonic inflammation.
• Precision Medicine: Understanding the specific cell types involved in these interactions (e.g., Fibroblast-Macrophage for CXCL12-CXCR4) could enable the development of more targeted therapies that modulate intercellular communication with greater specificity, potentially reducing off-target effects.
• Understanding Disease Heterogeneity: The distinction between 'Inflamed' and 'Non-inflamed' conditions, coupled with the differential CCI patterns, suggests underlying biological differences that may explain varied clinical presentations or responses to treatment. Further characterization of the 'Non-inflamed' state's unique CCI landscape could reveal mechanisms of disease remission or susceptibility.
• Epithelial Barrier Function: Altered integrin and adhesion molecule interactions involving intestinal epithelial cells underscore their critical role in maintaining barrier integrity, which is often compromised in colonic inflammation. Therapies aimed at restoring healthy epithelial-stromal interactions could promote mucosal healing.

11. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in Intestinal Epithelial cells (IECs) across Healthy, Inflamed, and Non-inflamed colon samples. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each sample. The objective is to highlight markers associated with inflammatory conditions, describe their underlying biological mechanisms, and evaluate their potential as therapeutic targets for colonic inflammation. The analysis focused exclusively on surfaceome markers, with an attempt to identify up to 50 markers per condition that meet specific fold change and non-zero percentage expression criteria.

Visual Summary

The dot plot provides a clear visual differentiation of surfaceome marker expression across the three experimental conditions:

• Healthy Samples: These samples generally show a lower overall expression and prevalence of most identified markers, typically appearing as smaller, lighter-colored dots. This indicates a relatively quiescent state of IECs concerning these inflammation-associated surface markers.
• Inflamed Samples: A striking and consistent upregulation of a broad panel of surfaceome markers is observed across nearly all 'Inflamed' samples. This is characterized by large, dark red dots, signifying both high mean expression and a large fraction of IECs expressing these markers. This pattern strongly suggests widespread cellular activation and significant functional alterations in IECs during colonic inflammation.
• Non-inflamed Samples: The 'Non-inflamed' group exhibits a heterogeneous expression profile. While some samples (e.g., Non-inflamed N661, N24, N23) present a marker signature closely resembling that of the 'Inflamed' group, others show intermediate expression levels or patterns more akin to 'Healthy' samples. This heterogeneity suggests a spectrum of cellular states within the 'Non-inflamed' classification, potentially indicating subclinical inflammation, early stages of disease, or a state of remission rather than a truly quiescent baseline.

Key clusters of genes notably upregulated in both Inflamed and a subset of Non-inflamed samples include Major Histocompatibility Complex (MHC) class II related genes (e.g., HLA-DRA, HLA-DRB1, CD74, HLA-DMA, HLA-DPA1), mucins (e.g., MUC1, MUC4, MUC12, MUC13), cell adhesion molecules (e.g., CEACAM5, DSG2), integrins (e.g., ITGA6, ITGB1), and other surface receptors such as CD44 and SDC1.

Biological Interpretation

The differential expression of specific surfaceome markers in Intestinal Epithelial Cells (IECs) provides crucial insights into the biological mechanisms active during colonic inflammation. Many of these markers play roles in cellular communication, immune modulation, and the maintenance of epithelial barrier function.

1. Immune Presentation and Communication:

• HLA-DRA, HLA-DRB1, HLA-DMA, HLA-DPA1 (MHC Class II molecules) and CD74 (Invariant Chain): The pronounced upregulation of MHC Class II genes, along with the invariant chain CD74, is a significant finding. This suggests that IECs in inflamed and some non-inflamed conditions gain or enhance their capacity for antigen presentation. Unlike professional antigen-presenting cells, IECs typically have low MHC Class II expression. This aberrant expression allows IECs to present antigens directly to CD4+ T cells, potentially initiating or perpetuating T-cell mediated immune responses against luminal contents or self-antigens, a key mechanism in chronic inflammatory bowel diseases (IBD).
• *Associated Signaling Pathways:* T-cell receptor (TCR) signaling upon MHC-peptide presentation; interferon-gamma (IFN-γ) signaling, which is a potent inducer of MHC Class II in non-professional APCs.
• *Biological Mechanisms:* Antigen presentation, T-cell activation, immune surveillance, and potential contribution to autoimmune responses within the gut mucosa.
• *Reference:* PubMed search: Intestinal epithelial cells MHC class II antigen presentation inflammation

2. Cell Adhesion, Barrier Integrity, and Tissue Remodeling:

• CEACAM5 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5): CEACAM5 is a cell adhesion molecule upregulated in inflamed IECs. It mediates homophilic and heterophilic interactions, affecting cell adhesion, differentiation, and survival. In inflammation, its increased expression may reflect altered cell adhesion dynamics, attempts at epithelial restitution, or enhanced interactions with immune cells.
• *Associated Signaling Pathways:* Pathways related to cell adhesion and potentially downstream signaling impacting proliferation and survival.
• *Biological Mechanisms:* Cell-cell adhesion, regulation of epithelial architecture, immune cell binding.
• *Reference:* GeneCards: CEACAM5
• ITGA6 (Integrin Alpha-6) and ITGB1 (Integrin Beta-1): These subunits form the integrin α6β1, a laminin receptor critical for cell-extracellular matrix (ECM) interactions. Their upregulation suggests significant remodeling of the IEC basement membrane interactions during inflammation. This can influence epithelial cell migration for wound healing, changes in barrier function, or responses to an altered ECM environment characteristic of inflammatory conditions.
• *Associated Signaling Pathways:* Focal adhesion kinase (FAK), Rho GTPases, and PI3K/Akt pathways, which regulate cell survival, proliferation, and migration.
• *Biological Mechanisms:* Cell-ECM adhesion, epithelial barrier integrity, cell migration and restitution, and mechanotransduction.
• *Reference:* UniProt: ITGA6, UniProt: ITGB1
• CD44 (CD44 Molecule): As a primary receptor for hyaluronan (HA), CD44 is involved in cell-cell and cell-matrix interactions, cell migration, and immune cell activation. Its upregulation in inflamed IECs can facilitate increased epithelial cell motility for repair, but also contribute to pro-inflammatory signaling by interacting with HA fragments (damage-associated molecular patterns, DAMPs) generated during inflammation.
• *Associated Signaling Pathways:* PI3K/Akt, MAPK, and NF-κB pathways, which are central to survival, proliferation, and inflammatory responses.
• *Biological Mechanisms:* Cell adhesion, migration, lymphocyte homing, inflammatory signaling, and epithelial stem cell functions.
• *Reference:* GeneCards: CD44
• SDC1 (Syndecan-1): This heparan sulfate proteoglycan plays roles in cell adhesion, growth factor signaling, and immune regulation. Upregulation of SDC1 in inflamed IECs can modulate interactions with various ligands, including growth factors and chemokines, thereby impacting epithelial proliferation, differentiation, and the local inflammatory microenvironment.
• *Associated Signaling Pathways:* FGF, HGF, and Wnt pathways.
• *Biological Mechanisms:* Cell adhesion, co-receptor for growth factors, ECM organization, and regulation of immune cell recruitment.
• *Reference:* GeneCards: SDC1
• DSG2 (Desmoglein-2): A cadherin family protein integral to desmosomes, which provide mechanical stability to epithelial tissues. Altered DSG2 expression or function can directly impact epithelial barrier integrity, a critical aspect of colonic inflammation. Its upregulation might be a compensatory mechanism to strengthen cell junctions or reflect altered adhesion dynamics.
• *Associated Signaling Pathways:* Desmosomal complex assembly and regulation of cell-cell adhesion.
• *Biological Mechanisms:* Epithelial cell adhesion, maintenance of barrier function, and tissue integrity.
• *Reference:* GeneCards: DSG2

3. Mucosal Protection and Glycocalyx Remodeling:

• MUC1, MUC4, MUC12, MUC13 (Mucins): These transmembrane mucins contribute to the glycocalyx, forming a protective barrier on the apical surface of IECs. Their upregulation in inflamed conditions often represents a compensatory mechanism to reinforce the mucosal barrier against luminal threats, protect against damage, and alter bacterial adherence.
• *Associated Signaling Pathways:* EGFR signaling and NF-κB pathway, which are involved in stress responses and inflammation.
• *Biological Mechanisms:* Mucosal barrier defense, cell protection, lubrication, and immune modulation.
• *Reference:* PubMed search: Mucins intestinal inflammation

4. Other Notable Markers:

• APP (Amyloid Beta Precursor Protein): Although widely known for its role in neurodegenerative diseases, APP is expressed in various tissues. Its upregulation in inflamed IECs might suggest roles in epithelial cell adhesion, signaling, or stress responses, potentially linking to the gut-brain axis, given the presence of enteric neurons in the colon.
• *Reference:* GeneCards: APP
• TSPAN13, TSPAN6 (Tetraspanins): These membrane proteins organize membrane microdomains and facilitate interactions between cell surface molecules. Their upregulation could impact a range of cellular processes, including cell migration, adhesion, and signaling, potentially fine-tuning inflammatory responses or repair mechanisms in IECs.
• *Reference:* UniProt: TSPAN13

Clinical or Translational Implications

The identification of these specific surfaceome markers on Intestinal Epithelial Cells, particularly their upregulation in the context of colonic inflammation, opens several promising avenues for clinical translation.

• Diagnostic and Prognostic Biomarkers: The distinct expression signatures observed, especially for markers like MHC Class II genes, CEACAM5, and mucins, could serve as valuable biomarkers. These could aid in the non-invasive or minimally invasive detection of active colonic inflammation, help stratify disease severity, predict disease course, or monitor the efficacy of therapeutic interventions. The heterogeneity noted in the "Non-inflamed" group further suggests these markers could be crucial for identifying patients who are clinically "non-inflamed" but still harbor molecular inflammation, guiding personalized treatment strategies.

Therapeutic Targets:

• MHC Class II on IECs: Given their role in aberrant antigen presentation, strategies to modulate or suppress MHC Class II expression or function specifically on IECs could reduce local T-cell activation and inflammation. This would require highly targeted approaches to avoid systemic immunosuppression.
• CEACAM5: As a cell adhesion molecule implicated in inflammation, CEACAM5 represents a tangible therapeutic target. Monoclonal antibodies against CEACAM5 are already under investigation in oncology. Developing similar targeted therapies to block CEACAM5-mediated pro-inflammatory interactions or signaling pathways in the colon could prove beneficial.
• Integrins (ITGA6/ITGB1): Integrins are validated therapeutic targets in inflammatory bowel disease, as exemplified by the anti-α4β7 integrin antibody vedolizumab. Targeting the α6β1 integrin, which influences IEC adhesion and migration, could offer a complementary strategy to bolster epithelial barrier integrity and support tissue repair in inflammation. Careful consideration of specificity and potential off-target effects would be essential.
• CD44: Modulation of CD44 activity could be therapeutic. Strategies targeting CD44 or its interaction with hyaluronan are being explored in other inflammatory contexts. In the gut, this could involve dampening pro-inflammatory signaling induced by HA fragments or enhancing epithelial restitution processes.
• Mucins (MUC1, MUC12, MUC13): As crucial components of the mucosal barrier, agents that promote healthy mucin production, improve their glycosylation, or stabilize the mucin layer could enhance gut protection against inflammatory triggers. While direct targeting is complex, this area holds potential for supportive therapies.
• Experimental Validation: To translate these findings into clinical applications, further experimental validation is critical. This should involve:
• Functional Assays: Investigating the impact of marker overexpression or knockdown on key IEC functions such as proliferation, migration, barrier integrity (e.g., transepithelial electrical resistance), and cytokine/chemokine production using *in vitro* models (e.g., intestinal organoids, 2D cultures) under inflammatory conditions.
• Cell-Cell Interaction Studies: Elucidating how altered IEC surfaceome profiles affect interactions with immune cells (e.g., T cells, macrophages) present in the inflamed colonic lamina propria.
• Preclinical Models: Testing the therapeutic potential of targeting these markers in *in vivo* models of colitis.
• Spatial Analysis: Utilizing spatial transcriptomics or proteomics to precisely map the localization and cell-type specificity of these markers within the complex tissue architecture of the inflamed human colon.

The differential expression of these surfaceome markers in IECs during inflammation underscores the active role of the epithelium in disease pathogenesis and offers a rich landscape for the discovery of novel diagnostic tools and therapeutic targets for colonic inflammation.

12. Macrophage Surfaceome Marker Expression in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression patterns of surfaceome markers in Macrophage cells isolated from human Colon tissue across three distinct conditions: Healthy, Inflamed, and Non-inflamed. The objective is to identify cell surface proteins that are differentially expressed in macrophages, providing insights into their functional states during colonic inflammation and potentially highlighting novel therapeutic targets. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each sample, grouped by condition. Markers were selected based on specific differential expression criteria and restricted to surfaceome genes, aiming to identify condition-specific signatures.

Visual Summary

The dot plot effectively illustrates distinct macrophage surfaceome profiles associated with different colonic conditions:

• Healthy Macrophage Signature: Macrophages from Healthy colon samples are characterized by prominent expression of a cluster of markers including LY6E, HLA-DQB2, ADORA3, ITM2C, CD68, TNFSF13B, PTPRC, and CYBB. These markers show markedly lower or absent expression in both Inflamed and Non-inflamed samples, suggesting their role in macrophage homeostasis.
• Inflamed and Non-inflamed Macrophage Shared Signature: A large group of markers, encompassing FCGR2A, TMEM123, APLP2, CD44, CLEC7A, FPR3, CSF1R, EVI2B, CD86, and GPR34, is highly expressed in macrophages from both Inflamed and Non-inflamed conditions. This shared signature suggests a common activation or altered functional state distinguishing these conditions from the Healthy state, indicating that even "Non-inflamed" tissue harbors macrophages with a significantly altered phenotype compared to truly healthy tissue. CD44 shows broad expression across all conditions but with elevated mean expression and fraction of cells in the Inflamed and Non-inflamed groups.
• Inflamed Macrophage Specific Signature: A distinct subset of markers, including ICAM1, RNF13, LAMP2, TGOLN2, AXL, and notably IL10RA, displays pronounced and often exclusive expression in macrophages from Inflamed samples. IL10RA shows particularly high expression and prevalence within the Inflamed group, highlighting its potential role in modulating severe inflammation.

In summary, the observed expression patterns reveal a clear phenotypic shift in macrophages during colonic inflammation, with unique surface markers identifying different stages or types of immune activation.

Biological Interpretation

Markers Predominant in Healthy Macrophages

These markers likely reflect the homeostatic, immune surveillance, and tissue maintenance roles of macrophages in a non-inflammatory environment.

• LY6E: Signaling & Mechanism: A glycosylphosphatidylinositol-anchored protein involved in immune cell activation and signaling pathways, potentially modulating T cell responses and cytokine production. In healthy macrophages, it might contribute to basal immune regulation or cell-cell interactions crucial for tissue integrity. Therapeutic Potential: Less studied as a direct therapeutic target for inflammation, but understanding its role in maintaining immune quiescence could inform strategies to restore tissue health. GeneCards: LY6E
• HLA-DQB2: Signaling & Mechanism: A component of the Major Histocompatibility Complex (MHC) Class II, essential for presenting extracellular antigens to CD4+ T helper cells, thereby initiating adaptive immune responses. Its expression in healthy macrophages indicates a baseline capacity for immune surveillance and antigen presentation of self or commensal antigens. Therapeutic Potential: Generally not a direct target, but manipulating MHC-II pathways is relevant in autoimmune diseases. GeneCards: HLA-DQB2
• ADORA3: Signaling & Mechanism: The A3 adenosine receptor, a G protein-coupled receptor. Adenosine signaling is a crucial regulator of inflammation, and ADORA3 activation often exerts anti-inflammatory or cytoprotective effects by modulating cytokine release and immune cell function. Therapeutic Potential: ADORA3 agonists have been investigated as anti-inflammatory agents in various disease models. GeneCards: ADORA3
• ITM2C: Signaling & Mechanism: Integral Membrane Protein 2C. Its precise function in macrophages is not extensively characterized, but integral membrane proteins are generally involved in cell structure, adhesion, or transport. Therapeutic Potential: Its specific role in immune regulation or inflammation is not well-defined, thus not a clear therapeutic target at present. GeneCards: ITM2C
• CD68: Signaling & Mechanism: A highly glycosylated transmembrane protein primarily found on macrophages and monocytes, acting as a scavenger receptor. It is involved in phagocytosis of cellular debris, oxidized lipids, and apoptotic cells, playing a key role in tissue homeostasis and waste removal. Therapeutic Potential: Widely used as a histological marker for macrophages; direct targeting is not a common therapeutic strategy, but its expression reflects overall macrophage activity. UniProt: CD68
• TNFSF13B (BAFF): Signaling & Mechanism: Tumor Necrosis Factor Superfamily Member 13B, also known as B-cell Activating Factor. Macrophage-derived BAFF is a crucial cytokine that promotes the survival, proliferation, and maturation of B cells. In healthy tissue, it may contribute to the maintenance of local B cell populations and humoral immunity. Therapeutic Potential: Inhibitors of BAFF (e.g., Belimumab) are clinically used to reduce B cell hyperactivity in autoimmune conditions, suggesting a potential role in colonic inflammation where B cell involvement is significant. GeneCards: TNFSF13B
• PTPRC (CD45): Signaling & Mechanism: Protein Tyrosine Phosphatase Receptor Type C, a transmembrane glycoprotein expressed on all hematopoietic cells (except mature erythrocytes) and critical for regulating immune cell activation. It dephosphorylates key signaling molecules, influencing the activation thresholds of T and B cell receptors and macrophage signaling. Therapeutic Potential: Due to its broad expression and fundamental role in immune cell function, CD45 is not typically a direct therapeutic target for specific inflammatory conditions. UniProt: PTPRC
• CYBB (NOX2): Signaling & Mechanism: Cytochrome B-245 Beta Chain, a catalytic subunit of the NADPH oxidase complex (NOX2). This enzyme is responsible for producing reactive oxygen species (ROS) in phagocytes, crucial for host defense against pathogens and modulation of inflammatory responses. Constitutive expression in healthy macrophages suggests a baseline antimicrobial and immune regulatory function. Therapeutic Potential: Inhibitors of NOX2 have been investigated for conditions associated with excessive ROS production and inflammation, but careful consideration is required due to its essential role in host defense. GeneCards: CYBB

Markers Enriched in both Inflamed and Non-inflamed Macrophages (relative to Healthy)

These markers point to a general activation or altered state of macrophages in non-healthy colonic tissue, potentially reflecting initial immune responses or chronic immune engagement.

• FCGR2A (CD32a): Signaling & Mechanism: Fc Gamma Receptor IIa, an activating Fc receptor that binds the Fc portion of IgG antibodies. Upon ligand binding, it triggers intracellular signaling cascades (via ITAM motifs), leading to phagocytosis, antigen presentation, antibody-dependent cellular cytotoxicity (ADCC), and the release of inflammatory mediators. Its upregulation suggests an enhanced capacity for antibody-mediated immune responses. Therapeutic Potential: Modulating FcR activity is a strategy in autoimmune and inflammatory diseases. Blocking FCGR2A could reduce excessive inflammatory responses driven by immune complexes. UniProt: FCGR2A
• TMEM123: Signaling & Mechanism: Transmembrane protein 123. Its specific function in macrophage biology or inflammation is not yet well-elucidated, but transmembrane proteins often play roles in cell adhesion, signaling, or transport. Therapeutic Potential: Currently, there is no established therapeutic potential due to limited understanding of its role. GeneCards: TMEM123
• APLP2: Signaling & Mechanism: Amyloid Beta Precursor Like Protein 2. While commonly associated with neuronal function, APLP2 has roles in cell adhesion and growth factor signaling. Its specific contribution to macrophage function in inflammation is not directly established, but could be related to cell-matrix interactions or immune cell development. Therapeutic Potential: Not a primary therapeutic target in inflammatory diseases. GeneCards: APLP2
• CD44: Signaling & Mechanism: A transmembrane glycoprotein and adhesion molecule that serves as a receptor for hyaluronic acid and other extracellular matrix components. It is involved in cell-cell and cell-matrix interactions, cell migration, lymphocyte activation, and can modulate signaling pathways (e.g., Rho GTPases). Upregulation in inflammation promotes cell adhesion and migration, and can influence cytokine production. Therapeutic Potential: CD44 antagonists or antibodies have been explored to inhibit immune cell migration and reduce inflammation, particularly in cancer and autoimmune diseases. UniProt: CD44
• CLEC7A (Dectin-1): Signaling & Mechanism: C-Type Lectin Domain Family 7 Member A, also known as Dectin-1. It functions as a pattern recognition receptor (PRR) that primarily recognizes β-glucans from fungi and certain endogenous ligands. Dectin-1 activation triggers Syk kinase signaling, leading to NF-κB activation, production of pro-inflammatory cytokines (e.g., TNFα, IL-6), and enhanced phagocytosis. It is critical for antifungal immunity and also implicated in sterile inflammation. Therapeutic Potential: Modulating Dectin-1 signaling could be a therapeutic strategy for fungal infections or specific types of sterile inflammatory conditions. UniProt: CLEC7A
• FPR3: Signaling & Mechanism: Formyl Peptide Receptor 3, a G protein-coupled receptor (GPCR) that binds formyl peptides. While other FPRs are well-known for mediating chemotaxis, FPR3's role in macrophages is less defined but implicated in modulating inflammatory responses, potentially exerting pro-resolving or anti-inflammatory effects depending on the context and ligand. Therapeutic Potential: As a GPCR, it represents a potentially druggable target. Further research into its precise role in colonic inflammation could lead to novel immunomodulatory agents. GeneCards: FPR3
• CSF1R (CD115): Signaling & Mechanism: Colony Stimulating Factor 1 Receptor, the receptor for M-CSF and IL-34. CSF1R signaling is essential for the survival, proliferation, differentiation, and polarization of macrophages. High expression indicates dependence on these cytokines, suggesting active macrophage recruitment and maintenance of the macrophage pool in the colon. Therapeutic Potential: CSF1R inhibitors are actively investigated in cancer therapy to target tumor-associated macrophages and show promise in inflammatory and fibrotic conditions by depleting or reprogramming pathogenic macrophage populations. UniProt: CSF1R
• EVI2B: Signaling & Mechanism: Ecotropic Viral Integration Site 2B. Its specific function in immune cells, particularly macrophages, is not well-established, but it is a transmembrane protein. Therapeutic Potential: Currently, there is no established therapeutic potential. GeneCards: EVI2B
• CD86 (B7-2): Signaling & Mechanism: CD86 Molecule, a co-stimulatory molecule expressed on antigen-presenting cells (APCs) like macrophages. It binds to CD28 and CTLA-4 on T cells, providing the crucial second signal required for T cell activation, proliferation, and differentiation. Upregulation signifies enhanced capacity for T cell activation and inflammatory responses. Therapeutic Potential: Blocking the CD86-CD28 co-stimulatory pathway (e.g., with Abatacept) is a clinically approved strategy to dampen T cell activation in autoimmune diseases, suggesting relevance for T cell-driven colonic inflammation. UniProt: CD86
• GPR34: Signaling & Mechanism: G Protein-Coupled Receptor 34, primarily expressed on macrophages and mast cells. It is involved in sensing lysophosphatidic acid (LPA) and other lipid mediators, influencing intracellular calcium levels and downstream signaling to modulate immune and inflammatory responses. Therapeutic Potential: As a GPCR, it represents a potentially druggable target, but its specific contribution to the pathogenesis of colonic inflammation requires further investigation for therapeutic development. GeneCards: GPR34

Markers Predominant in Inflamed Macrophages

These markers are specifically associated with an active inflammatory state in the colon, reflecting roles in immune cell recruitment, sustained immune activation, or feedback mechanisms.

• ICAM1 (CD54): Signaling & Mechanism: Intercellular Adhesion Molecule 1, an adhesion protein expressed on endothelial cells and immune cells, including macrophages. It binds to LFA-1 (CD11a/CD18) on leukocytes, facilitating strong cell-cell adhesion and promoting leukocyte extravasation into inflamed tissues. Its upregulation is a hallmark of inflammation, crucial for immune cell recruitment. Therapeutic Potential: Antibodies targeting ICAM1 or its ligands have been explored to reduce immune cell infiltration and inflammation in various inflammatory diseases. UniProt: ICAM1
• RNF13: Signaling & Mechanism: Ring Finger Protein 13. This gene encodes an E3 ubiquitin ligase. E3 ligases play critical roles in regulating protein stability and signaling pathways, including those involved in immune responses and inflammation, by targeting proteins for ubiquitination. Therapeutic Potential: While E3 ligases are emerging therapeutic targets, the specific role of RNF13 in macrophage inflammation is not extensively characterized for direct therapeutic application. GeneCards: RNF13
• LAMP2: Signaling & Mechanism: Lysosomal Associated Membrane Protein 2. A key component of lysosomal membranes, involved in lysosome biogenesis, maintenance of lysosomal integrity, autophagy, and antigen processing. Its upregulation in inflamed macrophages may reflect increased lysosomal activity, enhanced degradation of cellular debris/pathogens, and altered antigen presentation. Therapeutic Potential: Not a direct therapeutic target, but its role highlights altered lysosomal function, which could be indirectly modulated to influence macrophage activity. UniProt: LAMP2
• TGOLN2: Signaling & Mechanism: Trans-Golgi Network Integral Membrane Protein 2. Involved in vesicle trafficking from the trans-Golgi network. This process is crucial for the transport and secretion of various cellular components, including inflammatory mediators and cell surface proteins. Therapeutic Potential: While involved in intracellular trafficking, its direct contribution to specific inflammatory signaling pathways in macrophages requires further investigation for therapeutic potential. GeneCards: TGOLN2
• AXL: Signaling & Mechanism: AXL Receptor Tyrosine Kinase, a member of the TAM (Tyro3, Axl, Mer) family of receptors. Activated by Growth Arrest-specific Protein 6 (GAS6), AXL is involved in cell survival, proliferation, migration, and efferocytosis (clearance of apoptotic cells). In macrophages, AXL signaling can promote immune suppression and dampen inflammation, but it can also be a pro-survival signal for macrophages in chronic inflammation, potentially contributing to disease persistence. Therapeutic Potential: AXL inhibitors are under investigation, primarily in oncology to overcome immune evasion, but could also be explored to modulate macrophage function in chronic inflammatory diseases where AXL contributes to pathogenesis or immune tolerance. UniProt: AXL
• IL10RA (CD210): Signaling & Mechanism: Interleukin 10 Receptor Subunit Alpha, the primary binding component for Interleukin-10 (IL-10). IL-10 is a potent anti-inflammatory cytokine that suppresses pro-inflammatory cytokine production, inhibits antigen presentation, and promotes immune tolerance. Upregulation of IL10RA suggests that macrophages in inflamed tissue are highly receptive to IL-10 signaling, representing an endogenous feedback mechanism to control or resolve inflammation. Therapeutic Potential: Enhancing IL-10 pathway activation in macrophages, perhaps through targeted IL-10 delivery or by sensitizing cells to IL-10, could be a strategy to promote resolution of colonic inflammation. UniProt: IL10RA

Clinical or Translational Implications

The identified condition-specific macrophage surfaceome markers offer significant clinical and translational insights for colonic inflammation:

1. Biomarker Discovery: The distinct surface profiles of macrophages across Healthy, Non-inflamed, and Inflamed conditions present excellent candidates for diagnostic, prognostic, or predictive biomarkers. Markers like FCGR2A, CLEC7A, CD86, ICAM1, AXL, and IL10RA could be leveraged to identify inflammatory states, monitor disease progression, assess treatment response, or even differentiate between active inflammation and a "non-inflamed but altered" state using techniques like flow cytometry on tissue biopsies.
2. Novel Therapeutic Targets:

• Anti-inflammatory Strategies: The upregulation of activating receptors such as FCGR2A, CLEC7A, CD86, and adhesion molecules like ICAM1 in inflamed and non-inflamed macrophages suggests that targeting these pathways could attenuate immune cell activation, reduce T cell co-stimulation, and limit immune cell infiltration into the colon. For instance, CSF1R inhibition is a promising approach to reduce pathogenic macrophage numbers or alter their pro-inflammatory phenotype.
• Immunomodulatory Approaches: The prominent expression of IL10RA in inflamed macrophages highlights the potential for exploiting endogenous anti-inflammatory pathways. Strategies aimed at enhancing IL-10 signaling, either by direct IL-10 administration or by increasing IL10RA availability/sensitivity, could promote inflammation resolution and tissue repair. Conversely, the role of AXL can be complex, sometimes promoting immune suppression; its targeting may require nuanced strategies depending on the specific phase and type of inflammation.

3. Understanding Disease Pathogenesis: The observation that macrophages in "Non-inflamed" samples share many activated surface markers with "Inflamed" samples, distinct from "Healthy", implies that the "Non-inflamed" state may not be truly quiescent at the cellular level. This suggests a continuum of macrophage activation, which could be critical for understanding disease initiation, smoldering inflammation, or subclinical disease activity in conditions like Inflammatory Bowel Disease.

Further investigation through *in vitro* functional assays, *in vivo* disease models, and validation in larger patient cohorts will be crucial to translate these promising surfaceome markers into effective clinical tools and therapies for colonic inflammation.

13. Fibroblast Condition-Specific Surfaceome Marker Expression in Colonic Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of selected surfaceome markers in Fibroblast cells across different conditions: Healthy, Inflamed, and Non-inflamed colon tissue. The visualization helps to identify condition-specific fibroblast phenotypes based on surface protein expression, which are crucial for cell-cell interactions and environmental sensing. Markers were selected based on differential expression criteria (nz_pct_score and nz_pct FC) comparing conditions against each other or against a 'Healthy' reference. The plot uses individual samples grouped by condition, where dot size represents the fraction of cells expressing the marker in that sample, and color intensity (red scale) indicates the mean expression level within those expressing cells.

Visual Summary

The dot plot clearly segregates samples by their condition (Healthy, Inflamed, Non-inflamed), indicating distinct gene expression profiles among these groups of fibroblast populations.

• Healthy Fibroblasts: Samples from healthy individuals show high expression (dark red, large dots) of markers such as BST2, TM4SF1, CD74, THY1, CD59, and ATP1B3. These markers are generally diminished or absent in inflamed and non-inflamed samples.
• Inflamed Fibroblasts: Fibroblasts from inflamed samples exhibit a strong upregulation of several markers, including PDGFRA, MMP14, F3, VCAM1, IL6ST, ITGB1, SCARB2, LAMP2, and TMEM123. These markers are characterized by higher mean expression and/or a larger fraction of expressing cells compared to healthy samples. Many of these inflammatory markers are also present in non-inflamed samples, but often with reduced intensity or prevalence compared to the inflamed group.
• Non-inflamed Fibroblasts: The non-inflamed samples generally show an intermediate expression pattern between healthy and inflamed for many markers. For instance, while some inflammatory markers are present, their expression levels or cell prevalence are often lower than in the inflamed group. SCARA5 shows some expression in Healthy and Non-inflamed but is notably low in Inflamed.
• Overall Trends: There is a clear shift from a "quiescent" or homeostatic fibroblast profile in healthy tissue to an "activated" or pro-inflammatory/pro-fibrotic phenotype in inflamed tissue. The non-inflamed condition appears to represent a spectrum, sometimes closer to healthy, and sometimes exhibiting early signs or remnants of inflammatory activation.

Biological Interpretation

Markers Enriched in Healthy Fibroblasts

These markers likely contribute to the maintenance of tissue homeostasis and normal fibroblast functions in the colon. Their reduced expression in inflamed conditions may signify a loss of these homeostatic functions, contributing to disease pathology.

• BST2 (Bone Marrow Stromal Antigen 2 / CD317 / tetherin): Highly expressed in healthy fibroblasts and reduced in inflamed samples. BST2 is an interferon-inducible transmembrane protein involved in antiviral responses and immune regulation, capable of modulating cytokine production. In healthy colon fibroblasts, it may contribute to basal immune surveillance and maintaining an anti-inflammatory environment. GeneCards: BST2
• TM4SF1 (Transmembrane 4 L Six Family Member 1 / L6 antigen): Shows higher expression in healthy fibroblasts, indicating a potential role in normal cell adhesion, migration, or signal transduction within healthy colonic tissue. Its downregulation in inflammation might affect tissue integrity or fibroblast behavior. GeneCards: TM4SF1
• CD74 (CD74 Molecule / MHC Class II Invariant Chain): Predominantly expressed in healthy fibroblasts. CD74 is a chaperone for MHC class II molecules and also a receptor for Macrophage Migration Inhibitory Factor (MIF). In healthy fibroblasts, it might mediate homeostatic interactions with immune cells or regulate cellular responses to local growth factors. GeneCards: CD74
• THY1 (Thy-1 Cell Surface Antigen / CD90): A prominent marker in healthy fibroblasts, with reduced expression in inflamed samples. THY1 is a GPI-anchored glycoprotein involved in cell adhesion, migration, and signaling, playing diverse roles in inflammation, immunity, and fibrosis. Its high expression in healthy fibroblasts suggests a role in maintaining tissue architecture or regulating immune responses in a quiescent state. GeneCards: THY1
• CD59 (CD59 Molecule, Complement Regulator): Highly expressed in healthy fibroblasts. CD59 inhibits the formation of the membrane attack complex of the complement system, protecting cells from immune-mediated damage. Its reduction in inflamed tissue could render fibroblasts more vulnerable to complement attack, contributing to tissue damage. GeneCards: CD59
• ATP1B3 (ATPase Na+/K+ Transporting Beta 3 Subunit): Also found with higher expression in healthy fibroblasts. This subunit of the Na+/K+-ATPase pump is crucial for maintaining cellular ion gradients, essential for fundamental cellular processes. Its robust expression signifies healthy metabolic function. GeneCards: ATP1B3
• SCARA5 (Scavenger Receptor Class A Member 5): Relatively higher in healthy and non-inflamed samples compared to inflamed. SCARA5 is a scavenger receptor involved in clearance of modified proteins. In fibroblasts, it may contribute to tissue cleanup or sensing microenvironmental changes. GeneCards: SCARA5

Markers Enriched in Inflamed Fibroblasts

These markers are indicative of fibroblast activation, a process central to the inflammatory response, tissue remodeling, and fibrosis in colonic inflammation.

• PDGFRA (Platelet Derived Growth Factor Receptor Alpha): Strongly upregulated in inflamed fibroblasts. PDGFRA is a receptor tyrosine kinase that drives fibroblast proliferation, migration, and differentiation into myofibroblasts, which are key players in tissue repair and fibrosis. Its activation by PDGF ligands is a hallmark of many chronic inflammatory and fibrotic conditions, including inflammatory bowel disease. GeneCards: PDGFRA
• MMP14 (Matrix Metallopeptidase 14 / MT1-MMP): Significantly elevated in inflamed fibroblasts. MMP14 is a membrane-anchored matrix metalloproteinase that degrades extracellular matrix components and activates other MMPs. Its increased expression reflects heightened tissue remodeling, breakdown, and cellular invasion characteristic of chronic inflammation and fibrosis. GeneCards: MMP14
• F3 (Coagulation Factor III / Tissue Factor): Upregulated in inflamed fibroblasts. F3 initiates the extrinsic pathway of blood coagulation and also plays critical roles in inflammation, angiogenesis, and cell signaling. Its expression on fibroblasts can link coagulation cascades with inflammatory processes, contributing to both microthrombosis and inflammatory signaling in the inflamed colon. GeneCards: F3
• VCAM1 (Vascular Cell Adhesion Molecule 1 / CD106): Markedly upregulated in inflamed fibroblasts. VCAM1 is an adhesion molecule crucial for leukocyte recruitment to inflammatory sites by binding to VLA-4 integrin on immune cells. Its expression on fibroblasts promotes the infiltration of immune cells, exacerbating colonic inflammation. GeneCards: VCAM1
• IL6ST (Interleukin 6 Family Cytokine Receptor Subunit / gp130): Upregulated in inflamed fibroblasts. IL6ST is a common signaling component for receptors of IL-6 family cytokines, initiating JAK/STAT, MAPK, and PI3K pathways. Its enhanced expression suggests that inflamed fibroblasts are highly responsive to a broad range of pro-inflammatory and pro-fibrotic cytokines, driving chronic inflammation. GeneCards: IL6ST
• ITGB1 (Integrin Subunit Beta 1 / CD29): While present across conditions, its expression and prevalence appear higher in inflamed fibroblasts. ITGB1 forms heterodimers with various alpha integrins, mediating cell adhesion to the extracellular matrix and crucial for cell migration, proliferation, and mechanosensing. Upregulated ITGB1 signaling in inflamed fibroblasts supports their activation, migration within the inflamed tissue, and interaction with immune cells and ECM, contributing to inflammation and fibrosis. GeneCards: ITGB1
• SCARB2 (Scavenger Receptor Class B Member 2 / LIMP-2): Upregulated in inflamed fibroblasts. SCARB2 is a lysosomal membrane protein. Its increased expression may reflect altered lysosomal function, antigen processing, or stress responses in activated fibroblasts during inflammation. GeneCards: SCARB2
• LAMP2 (Lysosome Associated Membrane Protein 2 / CD107b): Upregulated in inflamed fibroblasts. LAMP2 is a lysosomal membrane glycoprotein involved in autophagy and lysosome biogenesis. Its elevation indicates increased lysosomal activity or stress responses in inflamed fibroblasts, potentially impacting antigen presentation or cellular debris clearance. GeneCards: LAMP2
• TMEM123 (Transmembrane Protein 123): Upregulated in inflamed fibroblasts. While its exact function is less characterized, its upregulation suggests involvement in inflammatory responses or cellular activation pathways. GeneCards: TMEM123

Markers with Less Distinct Patterns

• APP (Amyloid Beta Precursor Protein): Present across all conditions, with slightly lower expression in inflamed. APP is involved in cell adhesion and neural development, and its role in colon fibroblasts is likely related to general cellular functions or responses to stress. GeneCards: APP
• TFPI (Tissue Factor Pathway Inhibitor): Expressed across all conditions, with no clear strong differential pattern. TFPI is a natural anticoagulant, and its presence in fibroblasts suggests a role in regulating local coagulation, potentially to prevent excessive thrombosis. GeneCards: TFPI

Clinical or Translational Implications

The differential expression of these surfaceome markers on colonic fibroblasts provides insights into the molecular mechanisms underlying colonic inflammation and identifies potential therapeutic targets.

Therapeutic Targets for Colonic Inflammation

• PDGFRA: Given its central role in fibroblast activation and fibrosis, inhibiting PDGFRA signaling could be highly beneficial in reducing both inflammation and fibrosis in the colon.
• *Therapeutic Agents*: Tyrosine kinase inhibitors (TKIs) such as imatinib, nintedanib, or specific PDGFRA blockers could be explored. PubMed search: PDGFRA inhibitor inflammatory bowel disease
• VCAM1: As a key mediator of leukocyte recruitment, blocking VCAM1-mediated adhesion could reduce immune cell infiltration into the inflamed colon.
• *Therapeutic Agents*: Antibodies targeting VCAM1 or its ligand VLA-4 (e.g., natalizumab, vedolizumab, which targets α4β7) are already used in inflammatory bowel diseases and could be investigated for VCAM1 on fibroblasts. PubMed search: VCAM1 inhibitor inflammatory bowel disease
• MMP14: Its role in ECM degradation and tissue remodeling suggests that specific MMP14 inhibitors could ameliorate pathological tissue damage and fibrosis.
• *Therapeutic Agents*: While broad-spectrum MMP inhibitors have had limited clinical success, highly selective MMP14 inhibitors are being developed. PubMed search: MMP14 inhibitor inflammatory bowel disease
• IL6ST: Upregulation of gp130 indicates increased responsiveness to IL-6 family cytokines. Targeting IL6ST or its associated ligands could dampen a broad spectrum of inflammatory and pro-fibrotic signals.
• *Therapeutic Agents*: Antibodies blocking IL-6 (e.g., tocilizumab) or its receptor could be effective in dampening IL6ST-mediated signaling in fibroblasts. PubMed search: IL6ST inhibitor inflammatory bowel disease
• F3: Given its dual role in coagulation and inflammation, targeting F3 could offer a strategy to simultaneously address procoagulant and inflammatory aspects of colonic inflammation.
• *Therapeutic Agents*: Anticoagulants or novel compounds specifically targeting F3's non-coagulant signaling pathways. PubMed search: Tissue Factor inhibitor inflammatory bowel disease
• ITGB1: As a critical adhesion molecule, modulating ITGB1 function on fibroblasts could impact their activation, migration, and interaction with the microenvironment, potentially reducing inflammation and fibrosis.
• *Therapeutic Agents*: Integrin-blocking antibodies or small molecule inhibitors specific to ITGB1-containing integrins could be considered. PubMed search: ITGB1 inhibitor inflammatory bowel disease

Biomarkers for Disease Monitoring

• The panel of markers, particularly the clear distinction between healthy (e.g., THY1, BST2) and inflamed (e.g., PDGFRA, VCAM1) profiles, suggests their potential as diagnostic or prognostic biomarkers for assessing disease activity, progression, or therapeutic response in colonic inflammation. Monitoring the levels of these surface proteins on fibroblasts, perhaps via tissue biopsies or advanced imaging techniques, could provide valuable clinical information.

Understanding Disease Heterogeneity

• The expression differences between 'Inflamed' and 'Non-inflamed' for some markers (e.g., PDGFRA, MMP14) highlight the spectrum of disease activity and suggest that the 'Non-inflamed' tissue in patients might already harbor subclinical inflammatory changes or represent resolving/pre-inflammatory states. This suggests the importance of a nuanced approach to treatment and monitoring.

14. T cell CD4+ Condition-Specific Surfaceome Markers in Colonic Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression of surfaceome markers in CD4+ T cells across different colon tissue conditions: Healthy, Inflamed, and Non-inflamed. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for individual samples within each condition. Markers were identified based on differential expression comparisons against the 'Healthy' reference condition, focusing on surfaceome genes as requested by the user, with a limit of 40 markers per comparison, and specific cutoffs for nz_pct_score, nz_pct_FC, pval, and fc_cutoff. The goal is to identify and interpret markers that characterize CD4+ T cells in these distinct states, particularly in the context of colonic inflammation.

Visual Summary

The dot plot presents surfaceome marker expression patterns for CD4+ T cells across multiple individual samples, grouped by their condition (Healthy, Inflamed, Non-inflamed). Each row represents a sample, with a bar graph on the right indicating the total number of CD4+ T cells analyzed in that sample.

Key observations:

• Pan-T cell markers (PTPRC, CD7, CD3G): As expected, these markers, which are fundamental components of the T cell identity and receptor complex, show consistently high mean expression (dark red dots) and a high fraction of expressing cells (large dots) across nearly all samples in all three conditions. This confirms the robust identification of CD4+ T cells within the dataset.
• CD44: This marker exhibits a striking pattern. While present in Healthy samples, its mean expression and the fraction of expressing cells are substantially higher in both the Inflamed and Non-inflamed conditions. This suggests an elevated state of T cell activation or memory formation in these conditions compared to healthy tissue.
• CD27: This co-stimulatory marker shows notable expression, particularly prominent in samples from the Inflamed condition, both in terms of mean expression and prevalence. It is also present in Non-inflamed samples but appears more consistently upregulated in the Inflamed group.
• IL7R (CD127): This marker, important for T cell homeostasis and survival, shows variable but generally present expression across all conditions, with no clear trend of significant upregulation or downregulation specific to Inflamed or Non-inflamed states compared to Healthy within this visualization.
• KLRB1 (CD161): Expression of KLRB1 is also variable across samples and conditions. It is present in subsets of CD4+ T cells in Healthy, Inflamed, and Non-inflamed tissues, without a consistently strong differential pattern visible at this resolution.
• PTGPR4: This marker shows relatively low expression and cell prevalence across all conditions, indicating it is not a prominent surface marker on the majority of CD4+ T cells in this dataset.

In summary, the analysis highlights CD44 and CD27 as key surface markers that are distinctly upregulated on CD4+ T cells in conditions associated with colonic perturbations (Inflamed and Non-inflamed) compared to the Healthy state, indicating T cell activation and potential involvement in disease pathogenesis.

Biological Interpretation

Here, we delve into the biological roles of the identified surfaceome markers, focusing on their signaling pathways, mechanisms, and relevance within the colonic tissue and inferred inflammatory context.

Key Differentially Expressed Markers

1. CD44 (Hyaluronan Receptor)

• Signaling Pathways and Biological Mechanisms: CD44 is a widely expressed transmembrane glycoprotein that serves as a receptor for hyaluronan (HA) and other components of the extracellular matrix (ECM), such as osteopontin and fibronectin. On T cells, CD44 is crucial for adhesion, migration, and activation. Its expression is typically low on naive T cells but significantly upregulated upon T cell activation and differentiation into memory and effector cells. CD44 engagement can trigger downstream signaling pathways including Rho GTPases, PI3K/Akt, and MAPK, influencing cell survival, proliferation, and cytokine production. It plays a key role in guiding T cells to sites of inflammation by mediating interactions with endothelial cells and tissue matrix. GeneCards: CD44
• Role in Colonic Inflammation: The observed high expression and prevalence of CD44 on CD4+ T cells in both Inflamed and Non-inflamed colon samples, compared to Healthy, strongly indicates an activated or memory phenotype of these T cells. In colonic inflammation, CD44 upregulation likely facilitates T cell recruitment and retention within the inflamed mucosa, contributing to the persistent immune response and tissue damage. Interactions between CD44 on T cells and HA in the inflamed ECM can promote T cell survival and effector functions, exacerbating inflammatory pathology.

2. CD27 (TNFRSF7)

• Signaling Pathways and Biological Mechanisms: CD27 is a member of the TNF receptor superfamily, expressed on various lymphocyte subsets, including T cells. Its ligand, CD70, is primarily found on activated antigen-presenting cells (APCs), B cells, and other immune cells. The interaction between CD27 and CD70 provides crucial co-stimulatory signals that enhance T cell activation, proliferation, survival, and differentiation into long-lived memory T cells. CD27 signaling primarily engages TRAF2-dependent pathways, leading to activation of NF-κB and JNK, which are critical for T cell effector functions and protection against apoptosis. GeneCards: CD27
• Role in Colonic Inflammation: The increased expression and prevalence of CD27 on CD4+ T cells, particularly in the Inflamed colon, suggest an environment of active T cell co-stimulation and differentiation. This heightened CD27-CD70 axis activity would contribute to the expansion and sustained effector function of CD4+ T cells, potentially driving the chronic inflammatory process in the colon. Dysregulation of this co-stimulatory pathway can contribute to the pathogenesis of various inflammatory and autoimmune diseases.

Other Relevant Markers

3. IL7R (CD127)

• Signaling Pathways and Biological Mechanisms: The Interleukin-7 Receptor alpha chain (IL7R, CD127) is a crucial component of the receptor for IL-7, forming a heterodimer with the common gamma chain. IL-7/IL-7R signaling is vital for T cell development, survival, and homeostasis, especially for maintaining naive and memory T cell pools. Upon IL-7 binding, the receptor activates the JAK/STAT signaling pathway (specifically JAK1/JAK3 and STAT5), promoting anti-apoptotic gene expression (e.g., Bcl-2) and T cell proliferation. IL7R expression is typically high on naive and memory T cells and often downregulated upon sustained T cell activation into effector cells. GeneCards: IL7R
• Role in Colonic Inflammation: The variable yet consistent presence of IL7R on CD4+ T cells across all conditions suggests ongoing T cell homeostatic mechanisms or the persistence of memory T cell populations. While IL7R downregulation can mark terminal effector differentiation, its continued presence in inflamed tissue might indicate a balance between active responses and the maintenance of a memory pool, or incomplete effector differentiation. Alterations in the IL-7/IL-7R axis are implicated in inflammatory bowel disease, influencing lymphocyte survival and proliferation.

4. KLRB1 (CD161)

• Signaling Pathways and Biological Mechanisms: KLRB1 (Killer Cell Lectin Like Receptor B1), also known as CD161, is an inhibitory C-type lectin-like receptor expressed on NK cells, NKT cells, and a subset of T cells, including some CD4+ T cells. It binds to CLEC2D (LLT1). KLRB1 can modulate cytokine production and cytotoxicity. In T cells, KLRB1 is often associated with mucosal-associated invariant T (MAIT) cells and Th17 cells, both important in mucosal immunity. While its precise signaling in T cells is complex and context-dependent, it can influence T cell activation and differentiation. GeneCards: KLRB1
• Role in Colonic Inflammation: The variable expression of KLRB1 in CD4+ T cells in the colon suggests the presence of distinct T cell subsets known to reside in or traffic to mucosal sites. Given its association with Th17 cells, which are pro-inflammatory in many gut contexts, KLRB1-expressing CD4+ T cells could contribute to or modulate the inflammatory response in the colon.

General T cell Markers (Confirming Cell Identity)

5. PTPRC (CD45)

• Signaling Pathways and Biological Mechanisms: PTPRC (Protein Tyrosine Phosphatase Receptor Type C), commonly known as CD45, is a transmembrane glycoprotein abundantly expressed on all hematopoietic cells (except mature erythrocytes and megakaryocytes). It plays a critical role in regulating lymphocyte activation by dephosphorylating key signaling molecules, including Src family kinases (e.g., Lck, Fyn) and other substrates, thereby modulating T cell receptor (TCR) and B cell receptor (BCR) signaling thresholds. GeneCards: PTPRC
• Role in Colonic Inflammation: Its consistent high expression across all conditions confirms the robust identification of leukocytes, including CD4+ T cells. CD45 is essential for T cell function, and while its overall expression might not be a specific disease marker, its enzymatic activity is finely tuned during T cell activation, which is perturbed in inflammation.

6. CD7

• Signaling Pathways and Biological Mechanisms: CD7 is a transmembrane glycoprotein of the immunoglobulin superfamily, expressed on most T cells, NK cells, and some B cells. Its precise ligand and signaling mechanisms are not fully elucidated, but it is implicated in T cell activation, adhesion, and migration. It may play a role in mediating interactions with other immune cells or stromal components. GeneCards: CD7
• Role in Colonic Inflammation: Its widespread and high expression across all conditions indicates its status as a general T cell marker. While not specifically indicative of inflammation, its participation in T cell adhesive and activation processes could contribute to the overall immune cell dynamics in the colon.

7. CD3G (CD3 Gamma Chain)

• Signaling Pathways and Biological Mechanisms: CD3G is one of the invariant subunits of the CD3 complex, which is an integral part of the T cell receptor (TCR) complex. Together with CD3D, CD3E, and CD3Z (CD247), the CD3 complex is essential for signal transduction upon antigen recognition by the TCR. When the TCR binds to peptide-MHC complexes, the CD3 chains initiate intracellular signaling cascades (e.g., phosphorylation of ITAM motifs, activation of Lck and ZAP70) that lead to T cell activation, proliferation, and effector functions. GeneCards: CD3G
• Role in Colonic Inflammation: As a core component of the TCR complex, CD3G's uniform high expression confirms the presence of functional T cells capable of antigen recognition and signaling. In inflammatory conditions, while CD3G expression itself might not change dramatically, the downstream signaling pathways it initiates are highly active, driving the immune response.

8. PTGPR4 (Prostaglandin F2 Receptor Regulating PTGIR Expression)

• Signaling Pathways and Biological Mechanisms: PTGPR4 is involved in regulating the expression of PTGIR (Prostaglandin I2 Receptor). Prostaglandins are potent lipid mediators derived from arachidonic acid, playing critical roles in inflammation, pain, and various physiological processes. PGF2α (Prostaglandin F2 alpha), the primary ligand for PTGFR, often mediates pro-inflammatory and vasoconstrictive effects. PTGPR4's indirect role in prostaglandin signaling suggests a modulatory influence on lipid mediator pathways, which are highly active in inflammatory settings. GeneCards: PTGPR4
• Role in Colonic Inflammation: The relatively low expression of PTGPR4 observed suggests it is not a major or broadly expressed surface marker on CD4+ T cells in this context. While prostaglandins are critical in gut inflammation, direct signaling through PTGPR4 on CD4+ T cells appears to be minimal or restricted to a very small subset, and thus its direct contribution to the overall CD4+ T cell phenotype here is likely minor.

Clinical or Translational Implications

The identification of differentially expressed surfaceome markers on CD4+ T cells in inflamed colonic tissue offers potential avenues for understanding disease pathogenesis and developing targeted therapies.

CD44 as a Therapeutic Target:

• The significant upregulation of CD44 in both Inflamed and Non-inflamed conditions suggests that CD44-mediated adhesion and migration pathways are highly active in colonic inflammation.
• Therapeutic Potential: Modulating CD44 function could reduce T cell trafficking to and retention in the inflamed colon. Anti-CD44 antibodies or small molecules that block CD44-ligand (e.g., hyaluronan) interactions could potentially dampen inflammatory responses by inhibiting leukocyte infiltration and activation. For instance, in preclinical models of inflammatory bowel disease, inhibition of CD44 has shown promise in reducing intestinal inflammation. However, given CD44's broad expression, systemic inhibition might lead to off-target effects. Strategies focusing on specific CD44 isoforms or localized delivery might be more feasible. PubMed Search: CD44 colon inflammation therapeutic target

CD27 as a Therapeutic Target:

• The prominence of CD27 in Inflamed samples indicates active T cell co-stimulation via the CD27-CD70 axis. This pathway drives T cell proliferation and differentiation, which is essential for protective immunity but can be detrimental in chronic inflammation.
• Therapeutic Potential: Disrupting the CD27-CD70 interaction could limit excessive T cell activation and expansion in colonic inflammation. Therapeutic agents such as anti-CD70 antibodies have been explored in various immune disorders to inhibit T cell responses. Such an approach might reduce T cell-mediated pathology in inflammatory bowel disease by dampening pathogenic CD4+ T cell responses. PubMed Search: CD27 CD70 inflammation therapy
• IL7R and KLRB1: While less overtly differentially expressed in this plot, the IL-7/IL-7R axis is critical for T cell survival and can be dysregulated in inflammatory conditions. Similarly, KLRB1 marks specific T cell subsets (e.g., Th17 cells) that are central to gut inflammation. Further investigation into the specific states or subsets of CD4+ T cells expressing these markers, particularly in the inflamed colon, could reveal more refined therapeutic opportunities. Targeting IL-7R might modulate T cell survival and proliferation, while understanding the function of KLRB1-positive T cells could allow for targeted intervention in specific pro-inflammatory pathways. PubMed Search: IL7R inflammation therapy, PubMed Search: KLRB1 colon inflammation therapy

In conclusion, CD44 and CD27 emerge as particularly interesting candidate markers on CD4+ T cells in colonic inflammation, whose pathways could be explored for targeted immunomodulatory therapies. Further functional validation and investigation into the specific T cell subsets expressing these markers in vivo would be crucial to translate these findings into clinical applications.

15. Macrophage Gene Ontology Enrichment Analysis in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the biological pathways and Gene Ontology (GO) terms enriched in macrophages across different colonic conditions: Healthy, Inflamed, and Non-inflamed. The results are based on Gene Set Analysis (GSA) of up-regulated differentially expressed genes (DEGs) in macrophages, comparing each condition against a reference. Specifically, 'Inflamed' and 'Non-inflamed' conditions are compared to 'Healthy', while the 'Healthy' condition is compared to 'others' (i.e., 'Inflamed' and 'Non-inflamed' combined). The enrichment is visualized as bar plots, displaying the -log(p-val) and -log(q-val) for each enriched term, with higher values indicating greater statistical significance.

Visual Summary

The provided bar plots illustrate the top enriched GO terms and pathways in macrophages for three distinct comparisons:

1. GSA for Macrophage: Healthy_vs_others (Based on up-regulated DEGs)

This plot shows pathways whose associated genes are significantly upregulated in macrophages from healthy colon tissue when compared to macrophages from both inflamed and non-inflamed conditions. Top enriched terms include "Parkinson disease", "Prion disease", "Ribosome", "Amyotrophic lateral sclerosis", and "Oxidative phosphorylation". While some terms are related to neurodegenerative diseases, others like "Ribosome" and "Oxidative phosphorylation" point to fundamental cellular processes involved in protein synthesis and energy metabolism. This suggests that these basic homeostatic functions might be relatively more active or preserved in healthy macrophages compared to those in inflammatory states.

2. GSA for Macrophage: Inflamed_vs_Healthy (Based on up-regulated DEGs)

This plot highlights pathways significantly upregulated in macrophages from inflamed colon tissue when compared to healthy tissue. The most prominent terms are strongly indicative of an active immune and inflammatory response. These include "Coronavirus disease" (representing general viral response pathways), "Protein processing in endoplasmic reticulum", "NOD-like receptor signaling pathway", "Shigellosis", "Salmonella infection", "NF-kappa B signaling pathway", "Phagosome", "TNF signaling pathway", and "IL-17 signaling pathway". The high -log(q-val) values (up to ~7) denote strong statistical significance, consistent with robust immune activation.

3. GSA for Macrophage: Non-inflamed_vs_Healthy (Based on up-regulated DEGs)

This plot shows pathways upregulated in macrophages from non-inflamed colon tissue when compared to healthy tissue. Strikingly, the top enriched pathways are remarkably similar to those observed in the 'Inflamed_vs_Healthy' comparison. Key terms such as "Coronavirus disease", "Protein processing in endoplasmic reticulum", "Ribosome", "Lipid and atherosclerosis", "Salmonella infection", "Phagosome", "Endocytosis", "NOD-like receptor signaling pathway", "NF-kappa B signaling pathway", and "TNF signaling pathway" are highly significant. While the overall significance (maximum -log(q-val) around ~4) appears quantitatively lower than in the 'Inflamed_vs_Healthy' comparison, the qualitative pattern of activated pathways is highly conserved.

Biological Interpretation

The analysis reveals distinct and overlapping biological roles for macrophages in different states of colonic health and inflammation.

• Baseline Macrophage Activity in Health: In healthy colonic macrophages (when compared to both inflamed and non-inflamed states), there is a relative enrichment of genes involved in fundamental cellular processes such as protein synthesis ("Ribosome") and energy production ("Oxidative phosphorylation"). The appearance of neurodegenerative disease-related terms suggests that genes associated with these conditions, often linked to protein homeostasis and cellular stress responses, are more active or less dysregulated in a healthy, homeostatic state. This might reflect maintenance and housekeeping functions that are critical for tissue integrity but may be altered or suppressed during inflammation.
• Profound Immune Activation in Inflamed Macrophages: Macrophages in the inflamed colon exhibit a strong and broad activation of immune and inflammatory pathways. The upregulation of pathogen-sensing pathways like "NOD-like receptor signaling pathway" and "NF-kappa B signaling pathway" indicates a heightened state of innate immune surveillance and response to microbial threats. Pathways related to specific bacterial (e.g., "Shigellosis", "Salmonella infection") and viral (e.g., "Coronavirus disease") infections underscore the critical role of macrophages in host defense. Furthermore, the enrichment of "Phagosome" and "Endocytosis" pathways highlights increased cellular capacity for pathogen clearance and antigen presentation. Key inflammatory pathways such as "TNF signaling pathway" and "IL-17 signaling pathway" are activated, which are central orchestrators of chronic inflammation in the gut [1]. The activation of "Protein processing in endoplasmic reticulum" and "Ribosome" pathways suggests an increased demand for protein synthesis and processing, likely to support the production of immune mediators and cellular machinery for inflammatory responses, potentially also indicating ER stress.
• "Non-inflamed" as a Spectrum of Activation: The most striking finding is the significant overlap in activated pathways between macrophages from 'Inflamed' and 'Non-inflamed' conditions when compared to 'Healthy'. Macrophages in the 'Non-inflamed' colon also show robust activation of innate immune responses, pathogen defense, and inflammatory signaling (e.g., NOD-like receptor, NF-kappa B, TNF signaling). This suggests that the "Non-inflamed" state, within the context of individuals experiencing colonic issues, is not functionally equivalent to a truly healthy state. Instead, it likely represents a persistent low-grade inflammation, a state of chronic immune activation, or a heightened state of immune vigilance that may precede or follow overt inflammation. While the quantitative significance (lower -log(q-val) values for some pathways) might differentiate it from actively inflamed tissue, the qualitative biological processes are largely shared. This hints at the complexity of defining "non-inflamed" in a chronic inflammatory disease setting, where immune cells may remain primed or subtly activated even in the absence of acute clinical symptoms.

Clinical or Translational Implications

The profound activation of inflammatory and immune response pathways in macrophages during colonic inflammation offers critical insights for clinical and translational applications:

• Understanding Disease Progression: The similarity in macrophage pathway activation between 'Inflamed' and 'Non-inflamed' conditions suggests that a subclinical or persistent inflammatory signature exists even in clinically "non-inflamed" areas. This could be crucial for understanding disease recurrence, progression, and the concept of field effect in chronic inflammatory bowel diseases (IBD) [2]. The "non-inflamed" state may represent a crucial window for intervention to prevent disease exacerbation.
• Therapeutic Targets: Key pathways identified, such as NF-kappa B, TNF, and IL-17 signaling, are well-established targets for anti-inflammatory therapies in IBD [3, 4]. The specific enrichment of these pathways in colonic macrophages reinforces their role as central regulators of inflammation and potential targets for macrophage-specific drug delivery or modulation. Targeting macrophage activation, rather than just inflammatory cytokines, could offer novel therapeutic avenues.
• Biomarker Development: The unique profile of activated pathways in macrophages could serve as a source for novel biomarkers to assess inflammation severity, predict disease course, or monitor response to therapy, especially in distinguishing truly quiescent disease from a state of persistent subclinical inflammation. Gene expression signatures derived from these pathways could be evaluated for their diagnostic or prognostic value.
• Host-Pathogen Interactions: The consistent upregulation of pathways related to bacterial and viral infections highlights the constant interplay between the gut microbiome and host immune system in colonic inflammation. Understanding how macrophages respond to specific microbial antigens in different disease states could inform strategies involving microbiome modulation or targeted antimicrobial therapies.

---

References:

1. TNF Signaling: A major pathway in inflammation. PubMed search: TNF signaling pathway inflammation gut
2. IBD Field Effect: The concept of disease extending beyond macroscopically visible inflammation. PubMed search: inflammatory bowel disease field effect
3. NF-kappa B in IBD: Central role in inflammatory bowel diseases. PubMed search: NF-kappa B inflammatory bowel disease
4. IL-17 in IBD: Role in chronic gut inflammation. PubMed search: IL-17 inflammatory bowel disease

16. Gene Set Enrichment Analysis Reveals Cell-Type-Specific Pathway Dysregulation in Colonic Inflammation

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The goal was to identify pathways that are significantly enriched or depleted in different cell types under 'Inflamed' and 'Non-inflamed' conditions compared to a 'Healthy' reference state within the human colon tissue. The comparison for each celltype_minor was performed against the 'Healthy' reference condition, as specified by the use_ref=True parameter. The plot includes GSEA results for all specified cell types (B cell, Dendritic cell, Endothelial cell, Enteric glial cell, Fibroblast, Intestinal Epithelial cell, Macrophage, Mast cell, NK cell, Plasma cell, T cell CD4+, T cell CD8+). Each dot's size reflects the statistical significance (-log(p-value)), with larger dots indicating more robust enrichment. The color of the dot signifies the Normalized Enrichment Score (NES), where a red color indicates positive enrichment (pathway upregulation) and a blue color indicates negative enrichment (pathway downregulation). A comprehensive set of 120 pathways (n_pws_to_show) is displayed to provide a broad view of the affected biological processes.

Visual Summary

The dot plot provides a detailed landscape of pathway activity across various cell types and conditions.

• Overall Pattern: There is a pervasive and distinct pattern of pathway dysregulation observed, particularly in the 'Inflamed_vs_Healthy' comparisons, characterized by a high density of large, intensely colored dots. This indicates numerous highly significant changes in pathway activity during inflammation.
• Upregulated Pathways (Red Dots): A large number of pathways associated with immune activation, inflammatory responses, infection, and cellular proliferation are positively enriched. Prominent examples include "Cytokine-cytokine receptor interaction", "Chemokine signaling pathway", "NF-kappa B signaling pathway", "Toll-like receptor signaling pathway", "Th1 and Th2 cell differentiation", "T cell receptor signaling pathway", and "B cell receptor signaling pathway". Several infection-related pathways (e.g., "Salmonella infection", "Shigellosis", "Pathogenic Escherichia coli infection") also show strong upregulation. These pathways are broadly enriched across most immune cell types (T cells, B cells, Macrophages, Mast cells) and are also notably active in non-immune cells such as Intestinal Epithelial cells, Fibroblasts, and Endothelial cells.
• Downregulated Pathways (Blue Dots): Conversely, pathways related to specific metabolic processes, such as "Oxidative phosphorylation", "Fatty acid degradation", and "Insulin signaling pathway", exhibit negative enrichment (downregulation) in certain cell types under inflamed conditions. This suggests a metabolic shift in the diseased tissue.
• Cell Type Specificity: The analysis reveals clear cell-type-specific patterns of pathway alterations. For instance, "T cell receptor signaling pathway" and "Th1 and Th2 cell differentiation" are highly enriched predominantly in T cell subsets (CD4+ and CD8+), while "B cell receptor signaling pathway" is strongly active in B cells during inflammation. Intestinal Epithelial cells show significant changes in pathways like "Inflammatory bowel disease" and "Tight junction".
• Condition Differences: The 'Inflamed_vs_Healthy' comparisons generally display a higher number and greater statistical significance of enriched or depleted pathways compared to the 'Non-inflamed_vs_Healthy' comparisons. However, the 'Non-inflamed_vs_Healthy' conditions still show notable pathway alterations, suggesting that even macroscopically "non-inflamed" regions within a diseased colon may harbor molecular perturbations.

Biological Interpretation

• Core Inflammatory Signature: The widespread activation of immune signaling pathways (e.g., "Cytokine-cytokine receptor interaction", "NF-kappa B signaling pathway", "Toll-like receptor signaling pathway") across diverse cell types robustly confirms a strong inflammatory response in the colon. This indicates active cross-talk between immune and non-immune cells, characteristic of colonic inflammation [PubMed search: "colonic inflammation cytokine signaling NFkB" OR "toll-like receptor colitis"].
• Adaptive and Innate Immune Cell Activation: Both T cells (CD4+ and CD8+) and B cells show specific pathway activations ("T cell receptor signaling pathway", "B cell receptor signaling pathway", "Th1 and Th2 cell differentiation"), indicating their active involvement in adaptive immunity. Macrophages and Mast cells exhibit activation of innate immune pathways, highlighting their critical roles in initiating and perpetuating inflammation [GeneCards: NFKB1, TLR4; PubMed search: "T cell B cell activation inflammatory bowel disease"].
• Epithelial and Stromal Cell Contributions: Intestinal Epithelial cells show changes in "Inflammatory bowel disease" and "Tight junction" pathways, suggesting both a direct response to inflammation and potential compromises in gut barrier function. Fibroblasts and Endothelial cells also display inflammatory pathway enrichment, indicating their active participation in orchestrating the inflammatory microenvironment and tissue remodeling [PubMed search: "gut barrier tight junction inflammation" OR "fibroblast endothelial cell colon inflammation"].
• Metabolic Reprogramming: The downregulation of pathways like "Oxidative phosphorylation" and "Fatty acid degradation" suggests a shift in cellular metabolism, potentially towards glycolysis (Warburg effect). This metabolic reprogramming is common in activated immune cells and stressed tissues, supporting rapid proliferation and effector functions during inflammation [PubMed search: "immune cell metabolism inflammation" OR "colonic inflammation metabolic reprogramming"].
• Microbial Involvement: The strong enrichment of infection-related pathways (e.g., "Salmonella infection", "Shigellosis", "Pathogenic Escherichia coli infection") suggests a significant role of the gut microbiota in initiating or exacerbating colonic inflammation. Dysbiosis and altered host-microbe interactions are known drivers of inflammatory bowel diseases [PubMed search: "gut microbiota inflammatory bowel disease" OR "colitis pathogen response"].
• Cancer Risk: The observed enrichment of several cancer-related pathways (e.g., "Colorectal cancer", "Cell cycle", "p53 signaling pathway") is a notable finding. Chronic inflammation is a recognized risk factor for cancer development, and these pathway alterations may reflect increased cellular proliferation, DNA damage, and dysregulated cell death mechanisms that can precede malignant transformation in the inflamed colon [PubMed search: "inflammation colon cancer pathway" OR "colitis associated cancer mechanisms"].
• Nuances of Non-inflamed Condition: The detection of pathway alterations in 'Non-inflamed_vs_Healthy' samples suggests that even macroscopically healthy areas within an affected colon, or samples from subjects with a history of inflammation, may harbor subclinical molecular changes. This highlights the molecular heterogeneity of inflammatory conditions and the potential for persistent low-grade inflammation.

Clinical or Translational Implications

• Targeted Therapeutics: The identified cell-type-specific pathway enrichments provide a valuable roadmap for developing more targeted therapeutic strategies. For example, specific inhibitors of NF-κB or cytokine signaling pathways could be deployed, potentially with cell-type-specific delivery mechanisms, to precisely modulate inflammation while minimizing systemic side effects.
• Biomarker Discovery for Disease Activity and Risk: Genes within the highly enriched inflammatory and cancer-related pathways across different cell types could serve as novel biomarkers for diagnosing colonic inflammation, monitoring disease activity, predicting treatment response, or identifying patients at higher risk for inflammation-associated colorectal cancer.
• Understanding Disease Heterogeneity: The distinct GSEA profiles across various cell types and conditions ("Inflamed" vs. "Non-inflamed") underscore the molecular heterogeneity of colonic inflammation. This insight is crucial for personalized medicine approaches, allowing for tailored interventions based on a patient's specific cellular and molecular landscape.
• Prognostic Value: The presence and extent of enrichment in cancer-related pathways within inflamed and even non-inflamed tissues could offer prognostic value, indicating the potential for disease progression or malignant transformation.
• Role of Microbiome: The strong signal from infection-related pathways reinforces the critical role of the gut microbiome in colonic inflammation, suggesting that therapeutic strategies targeting microbial dysbiosis might be a beneficial approach for intervention.

17. Discussion

The single-cell RNA-sequencing analysis of human colon tissue provides an unparalleled depth of insight into the multifaceted nature of colonic inflammation. The UMAP visualizations confirm the profound cellular restructuring associated with the 'Inflamed' state, demonstrating distinct clustering that separates inflamed cells from healthy and non-inflamed counterparts. This cellular reorganization is driven by significant shifts in cell type proportions, notably a robust increase in B cells and plasma cells, indicating an activated humoral immune response. Macrophage populations exhibit striking plasticity, with a clear polarization towards a pro-inflammatory M1 phenotype in inflamed tissues, accompanied by a reciprocal decrease in M2A macrophages, which typically mediate resolution. Critically, M2B macrophages show a progressive increase from healthy to non-inflamed to inflamed states, suggesting a complex, potentially dual role in both promoting and regulating inflammation.

The T cell compartment reveals a nuanced picture. While regulatory T cells (Tregs), T follicular helper (Tfh) cells, Th22 cells, and CD8 Exhausted T cells show increased proportions in inflammation, the observed proportional *decrease* in pro-inflammatory Th1 and Th17 cells, as well as CD8 Memory T cells, is counter-intuitive if considering an acutely active inflammation driven solely by these effector populations. This could be explained by a relative dilution effect due to the massive expansion of other immune populations, or it may indicate a chronic or resolving inflammatory phase where T cell exhaustion, migration, or apoptosis play significant roles. This highlights the importance of complementing proportional data with absolute cell counts for a complete understanding.

Cell-cell interaction (CCI) analyses unveil a re-wiring of communication networks in the inflamed colon. Upregulated interactions involving IFN-γ signaling among T cells, Prostaglandin E2 in macrophages and epithelial cells, CXCL12-CXCR4 for immune cell trafficking, and VCAM1-integrin interactions for leukocyte extravasation underscore the heightened inflammatory signaling and immune cell recruitment. These interactions highlight the active participation of not only immune cells but also intestinal epithelial cells and fibroblasts in orchestrating and perpetuating inflammation and tissue remodeling.

Condition-specific surfaceome marker analysis provides a granular view of cell state changes. Intestinal Epithelial Cells in inflamed tissue exhibit increased expression of MHC Class II molecules, CEACAM5, and integrins (ITGA6/ITGB1), suggesting enhanced antigen presentation, altered adhesion, and compromised barrier function. Macrophages upregulate activating receptors (FCGR2A, CD86), adhesion molecules (ICAM1), and importantly, the IL-10 receptor (IL10RA), pointing to both active immune responses and intrinsic regulatory feedback. Fibroblasts display markers of activation and fibrosis (PDGFRA, MMP14, VCAM1, IL6ST), confirming their role in pathological tissue remodeling. CD4+ T cells show increased CD44 and CD27 expression, indicative of their activation and enhanced homing/co-stimulation capacities.

Gene Set Enrichment Analysis (GSEA) integrates these cellular changes into a comprehensive pathway-level understanding. A pervasive activation of immune and inflammatory pathways (e.g., NF-κB, TNF, IL-17 signaling, Toll-like receptor signaling) is observed across nearly all cell types in inflamed conditions. Furthermore, metabolic reprogramming (downregulation of oxidative phosphorylation) and enrichment of cancer-related pathways (e.g., colorectal cancer, cell cycle, p53 signaling) are alarming findings that underscore the chronic and potentially carcinogenic nature of prolonged colonic inflammation. A recurring theme across multiple analyses is the molecular distinction of the 'Non-inflamed' condition from 'Healthy' tissue. Macrophages from 'Non-inflamed' samples share numerous activated pathways and surface markers with 'Inflamed' macrophages, suggesting that 'Non-inflamed' regions may represent a state of subclinical inflammation, heightened immune vigilance, or residual molecular pathology rather than a return to full immunological quiescence.

In conclusion, this single-cell transcriptomic analysis provides a high-resolution molecular and cellular map of human colonic inflammation, identifying key drivers of pathogenesis, complex immune cell dynamics, and the intricate intercellular communication networks that govern disease progression. The insights into the 'Non-inflamed' state are particularly critical, highlighting a potential window for early intervention or improved disease monitoring beyond gross clinical assessment.

Hypotheses:

1. The 'Non-inflamed' colon tissue harbors a distinct molecular signature of persistent low-grade inflammation, characterized by activated macrophage polarization (M1/M2B) and primed T cell responses, which contributes to disease chronicity or recurrence.
2. The observed proportional decrease in Th1 and Th17 T cell subsets in 'Inflamed' colon is due to either their absolute numbers being diluted by the expansion of other immune cell populations, their exhaustion/migration out of the tissue, or the dataset representing a chronic/resolving inflammatory phase rather than an acute Th1/Th17-driven exacerbation.
3. Upregulated cell-cell interaction pathways (e.g., VCAM1-integrin, CXCL12-CXCR4) and specific surface markers (e.g., PDGFRA on fibroblasts, MHC Class II on intestinal epithelial cells) actively mediate chronic immune cell infiltration, drive pathological tissue remodeling, and contribute to epithelial barrier dysfunction in colonic inflammation.
4. The enrichment of cancer-related pathways in both 'Inflamed' and a subset of 'Non-inflamed' colonic cells signifies early molecular events predisposing to inflammation-associated colorectal cancer, even in the absence of overt malignancy.

Potential therapeutic targets:

1. IFN-γ / IFN-γ Receptor (IFNGR1/2): Strong upregulation of IFNG_Type_II_IFNR interactions among T cells in inflamed colon indicates active T-cell mediated inflammation. Evidence: CCI analysis (Section 9, 10) shows prominent IFN-γ signaling in inflamed T cell populations. Validation: Targeting IFN-γ or its receptor with specific inhibitors or antibodies in preclinical models of colitis to assess reduction in T-cell mediated inflammation and tissue damage.
2. Prostaglandin E2/D2 pathways (via PTGER2/4, PTGES2/3): Pervasive and strong upregulation of prostaglandin E2/D2 signaling in macrophages, epithelial cells, and fibroblasts in inflamed tissue drives cardinal inflammatory signs. Evidence: CCI analysis (Section 9, 10) highlights high expression of ProstaglandinD2_byPTGES2_PTGER4 and ProstaglandinE2_byPTGES3-PTGER2/4 interactions. GSEA (Section 16) shows enrichment of inflammatory pathways. Validation: Specific antagonists for EP2 or EP4 receptors in colitis models to evaluate efficacy in reducing inflammation and modulating immune/epithelial cell responses. Repurposing or developing specific prostaglandin synthesis inhibitors.
3. CXCL12 / CXCR4 axis: Highly active CXCL12-CXCR4 signaling, particularly between fibroblasts and immune cells, mediates immune cell trafficking and accumulation in the inflamed colon. Evidence: CCI analysis (Section 9, 10) shows strong and frequent CXCL12_CXCR4 interactions in inflamed samples, especially involving Fibroblasts and Macrophages/Plasma cells. Validation: Use of CXCR4 antagonists (e.g., Plerixafor or novel compounds) in preclinical colitis models to assess reduction in inflammatory cell infiltration and amelioration of inflammation.
4. VCAM1 / Integrin α4β1 complex: VCAM1-integrin α4β1 interactions facilitate leukocyte recruitment and extravasation into inflamed tissues, a hallmark of chronic inflammation. Evidence: CCI analysis (Section 10) and Fibroblast surfaceome (Section 13) show VCAM1 upregulation in inflamed tissue. CD4+ T cell surfaceome (Section 14) implies target integrin expression. Validation: Clinical utility of existing anti-integrin antibodies (e.g., Natalizumab, Vedolizumab) in IBD validates this target. Further investigation into fibroblast-expressed VCAM1 using specific blocking antibodies in vivo.
5. MHC Class II molecules on Intestinal Epithelial Cells (e.g., HLA-DRA, HLA-DRB1): Aberrant upregulation of MHC Class II on IECs allows them to present antigens to CD4+ T cells, potentially initiating or perpetuating local autoimmune-like responses. Evidence: IEC surfaceome analysis (Section 11) shows pronounced upregulation of MHC Class II genes (HLA-DRA, HLA-DRB1, CD74, HLA-DMA, HLA-DPA1) in inflamed IECs. Validation: Develop highly targeted strategies (e.g., specific small molecules or antibodies with IEC-specific delivery) to suppress MHC Class II expression or function on IECs in vitro (organoids) and in vivo (colitis models) without systemic immunosuppression.
6. CEACAM5: Upregulation of CEACAM5 on IECs in inflammation reflects altered cell adhesion and potential pro-inflammatory interactions. Evidence: IEC surfaceome analysis (Section 11) and CCI analysis (Section 9) show increased CEACAM5 expression and interactions in inflamed conditions. Validation: Utilize monoclonal antibodies against CEACAM5 (some in oncology development) to block its adhesion or signaling functions in IECs in vitro and in vivo models of colitis to assess impact on inflammation and epithelial integrity.
7. PDGFRA (Platelet Derived Growth Factor Receptor Alpha): Strong upregulation of PDGFRA in inflamed fibroblasts drives their proliferation, migration, and differentiation into myofibroblasts, central to fibrosis and tissue remodeling in chronic inflammation. Evidence: Fibroblast surfaceome analysis (Section 13) shows strong PDGFRA upregulation in inflamed fibroblasts. Validation: Test tyrosine kinase inhibitors (TKIs) like Imatinib or Nintedanib, or specific PDGFRA blockers, in preclinical models of colitis to assess their efficacy in reducing fibroblast activation, fibrosis, and overall inflammation.
8. MMP14 (Matrix Metallopeptidase 14): Elevated MMP14 in inflamed fibroblasts indicates heightened extracellular matrix degradation and tissue remodeling, contributing to pathological tissue damage and fibrosis. Evidence: Fibroblast surfaceome analysis (Section 13) shows significant MMP14 elevation in inflamed fibroblasts. Validation: Investigate selective MMP14 inhibitors in colitis models to determine their effect on tissue damage, fibrosis, and inflammatory markers.
9. IL6ST (gp130, IL-6 family cytokine receptor subunit): Upregulation of IL6ST in inflamed fibroblasts suggests increased responsiveness to IL-6 family cytokines, driving a broad spectrum of inflammatory and pro-fibrotic signals. Evidence: Fibroblast surfaceome analysis (Section 13) shows IL6ST upregulation in inflamed fibroblasts. Validation: Antibodies blocking IL-6 (e.g., Tocilizumab) or its receptor could be effective in dampening IL6ST-mediated signaling in fibroblasts in colitis models. Investigate specific inhibitors of gp130 signaling.
10. CSF1R (Colony Stimulating Factor 1 Receptor): High expression in activated macrophages indicates their dependence on CSF1/IL-34 signaling for survival, proliferation, and polarization, making it a critical regulator of macrophage populations in inflammation. Evidence: Macrophage surfaceome analysis (Section 12) shows high CSF1R expression in inflamed and non-inflamed macrophages. Validation: CSF1R inhibitors (under investigation in oncology) could be tested in colitis models to deplete pathogenic macrophage populations or reprogram their pro-inflammatory phenotype, thereby reducing inflammation.
11. IL10RA (Interleukin 10 Receptor Subunit Alpha): High expression of IL10RA in inflamed macrophages suggests they are highly receptive to the anti-inflammatory cytokine IL-10, representing an endogenous feedback mechanism to control inflammation. Evidence: Macrophage surfaceome analysis (Section 12) shows particularly high IL10RA expression in inflamed macrophages. Validation: Strategies aimed at enhancing IL-10 signaling, such as targeted IL-10 delivery or by sensitizing macrophages to IL-10, could promote resolution of colonic inflammation in preclinical models.
12. CD44: Significant upregulation of CD44 on CD4+ T cells and macrophages in inflamed and non-inflamed colon indicates active T cell and macrophage adhesion, migration, and activation, contributing to persistent immune responses. Evidence: CD4+ T cell (Section 14) and Macrophage (Section 12) surfaceome analyses show prominent CD44 upregulation. GSEA (Section 16) highlights related pathways. Validation: Use anti-CD44 antibodies or small molecules blocking CD44-hyaluronan interactions in colitis models to reduce T cell and macrophage infiltration and dampen inflammatory responses. Investigate isoform-specific targeting.
13. CD27 / CD70 axis: Prominence of CD27 on CD4+ T cells in inflamed samples indicates active T cell co-stimulation, leading to T cell proliferation and differentiation that can sustain chronic inflammation. Evidence: CD4+ T cell surfaceome analysis (Section 14) shows increased CD27 expression in inflamed CD4+ T cells. Validation: Disrupting CD27-CD70 interaction with therapeutic agents such as anti-CD70 antibodies (explored in other immune disorders) could limit excessive T cell activation and expansion in colitis models.

Follow-up validation ideas:

1. To validate the nature of 'Non-inflamed' tissue (Hypothesis 1), conduct longitudinal studies correlating macrophage activation markers and T cell priming in 'Non-inflamed' biopsies with future clinical outcomes (e.g., disease flares, progression). Perform functional assays on isolated macrophages from 'Non-inflamed' tissue (e.g., cytokine production, antigen presentation) and compare to 'Healthy' and 'Inflamed' states.
2. To clarify T cell subset dynamics (Hypothesis 2), quantify absolute numbers of Th1, Th17, and CD8 Memory T cells in tissue biopsies using multiplexed imaging or flow cytometry. Perform T cell exhaustion and activation marker analysis (e.g., PD-1, TIM-3) on these subsets. Investigate T cell migration patterns and fate using ex vivo tissue explant cultures or in vivo models of chronic colitis.
3. To confirm the roles of specific CCI and surface markers (Hypothesis 3), utilize in vitro co-culture models of intestinal epithelial cells, fibroblasts, and immune cells. Employ genetic perturbation (CRISPR/Cas9) or pharmacological inhibition of identified ligand-receptor pairs (e.g., VCAM1-integrin, CXCL12-CXCR4) or surface markers (e.g., PDGFRA) in these models and in preclinical models of colitis to assess impacts on immune cell infiltration, fibroblast activation, ECM deposition, and epithelial barrier function.
4. To investigate cancer predisposition (Hypothesis 4), perform genomic stability assays (e.g., DNA damage markers) and proliferation assays on IECs and fibroblasts from 'Inflamed' and 'Non-inflamed' tissues. Correlate enrichment of cancer-related pathways with long-term patient follow-up for incidence of dysplasia or colorectal cancer, and use spatial transcriptomics to map these changes in relation to tissue architecture.

Limitations:

Several limitations should be considered when interpreting these findings. Firstly, while the 'Inflamed' condition clearly represents an active inflammatory state, the 'Non-inflamed' group exhibits significant molecular and cellular heterogeneity, often displaying signatures intermediate to or overlapping with 'Inflamed' tissue. This suggests that 'Non-inflamed' may encompass a spectrum of states, including subclinical inflammation or tissue in remission, rather than a truly quiescent baseline. Further characterization and clinical correlation are needed to precisely define this group. Secondly, single-cell RNA-sequencing data provide proportional changes in cell populations and gene expression, which do not directly reflect absolute cell numbers or gene counts. This can impact the interpretation of population dynamics (e.g., a proportional decrease in a T cell subset might occur even if its absolute numbers are maintained or slightly increased due to the massive expansion of other cell types). Thirdly, the inference of 'Colonic Inflammation' as the overarching disease context is based on metadata (tissue source, conditions) and not on specific clinical diagnoses (e.g., Crohn's disease, ulcerative colitis). While highly relevant, the specific subtypes or etiologies of inflammation cannot be determined from the provided data. Fourthly, the analysis inherently lacks spatial information, limiting our understanding of cell-cell interactions and pathological processes within the complex tissue architecture. Lastly, while numerous potential therapeutic targets and biomarkers have been identified, these are based on transcriptomic data and require extensive functional validation through in vitro experiments, preclinical animal models, and ultimately, human clinical trials to confirm their efficacy and safety.

18. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Show and save a population bar plot of minor cell types.
5. Show and save a population bar plot of T cell subsets.
6. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
7. Show and save a population bar plot of macrophage subsets.
8. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
10. Find cell-cell interactions involving major tissue cells, immune cells and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
11. Show marker expression for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
12. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
13. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
14. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
15. Show Gene Ontology (GSA) analysis results for macrophages as a bar plot, and save the result.
16. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.